UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K/A

 

(Amendment No. 1)

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): August 4, 2015

 

VENTAS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

 

1-10989

 

61-1055020

(State or Other Jurisdiction
of Incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

353 N. Clark Street, Suite 3300, Chicago, Illinois

 

60654

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (877) 483-6827

 

Not Applicable

Former Name or Former Address, if Changed Since Last Report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

EXPLANATORY NOTE

 

On August 4, 2015, Ventas, Inc. (the “Company”) completed its acquisition of Ardent Medical Services, Inc. (“AHS”).  Concurrent with the closing of the transaction, the Company separated AHS’s hospital operations from its owned real estate and sold the hospital operations to a newly formed and capitalized operating company (“Ardent”).  The acquisition was originally reported on a Current Report on Form 8-K, filed by the Company with the Securities and Exchange Commission on August 10, 2015 (the “Original Filing”). This amendment to the Original Filing is being filed to provide the historical financial statements of AHS Medical Holdings (as defined below) and any additional information required by Item 9.01(a) and the pro forma financial information required by Item 9.01(b), which financial statements and information were not included in the Original Filing.

 

Item 9.01.                                        Financial Statements and Exhibits.

 

(a)         Financial Statements of Businesses Acquired.

 

The audited consolidated financial statements of AHS Medical Holdings LLC, the 100% parent company of AHS (“AHS Medical Holdings”), for the years ended December 31, 2014 and 2013 are filed herewith as Exhibit 99.1 and incorporated in this Item 9.01(a) by reference.  The unaudited condensed consolidated financial statements of AHS Medical Holdings for the six month periods ended June 30, 2015 and 2014 are filed herewith as Exhibit 99.2 and incorporated in this Item 9.01(a) by reference.

 

(b)         Pro Forma Financial Information.

 

The unaudited pro forma condensed consolidated financial information of the Company, giving effect to the acquisition of AHS and the concurrent sale of Ardent, and the related notes thereto, are filed herewith as Exhibit 99.3 and incorporated in this Item 9.01(b) by reference.

 

(c)          Shell Company Transactions.

 

Not applicable.

 

(d)         Exhibits:

 

Exhibit
Number

 

Description

 

 

 

23.1

 

Consent of Ernst & Young LLP.

 

 

 

99.1

 

Audited consolidated financial statements of AHS Medical Holdings LLC for the years ended December 31, 2014 and 2013.

 

 

 

99.2

 

Unaudited condensed consolidated financial statements of AHS Medical Holdings LLC for the six month periods ended June 30, 2015 and 2014.

 

 

 

99.3

 

Unaudited pro forma condensed consolidated financial information.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

VENTAS, INC.

 

 

 

 

 

 

Date: September 1, 2015

By:

/s/ T. Richard Riney

 

 

T. Richard Riney

 

 

Executive Vice President, Chief

Administrative Officer and General

Counsel

 

3



 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

 

 

 

23.1

 

Consent of Ernst & Young LLP.

 

 

 

99.1

 

Audited consolidated financial statements of AHS Medical Holdings LLC for the years ended December 31, 2014 and 2013.

 

 

 

99.2

 

Unaudited condensed consolidated financial statements of AHS Medical Holdings LLC for the six month periods ended June 30, 2015 and 2014.

 

 

 

99.3

 

Unaudited pro forma condensed consolidated financial information.

 

4




Exhibit 23.1

 

CONSENT OF INDEPENDENT AUDITORS

 

We consent to the incorporation by reference in the following Registration Statements:

 

(1)         Registration Statement (Form S-4 No. 333-198789) of Ventas, Inc.,

 

(2)         the Registration Statement (Form S-3 No. 333-202586) of Ventas, Inc.,

 

(3)         the Registration Statement (Form S-3 No. 333-200781) of Ventas, Inc.,

 

(4)         the Registration Statement (Form S-8 No. 333-183121) pertaining to the Ventas, Inc. 2012 Incentive Plan,

 

(5)         the Registration Statement (Form S-8 No. 333-173434) pertaining to the Nationwide Health Properties, Inc. 2005 Performance Incentive Plan, as Amended,

 

(6)         the Registration Statement (Form S-8 No. 333-136175) pertaining to the Ventas, Inc. 2006 Incentive Plan and Ventas, Inc. 2006 Stock Plan for Directors,

 

(7)         the Registration Statement (Form S-8 No. 333-126639) pertaining to the Ventas Employee and Director Stock Purchase Plan,

 

(8)         the Registration Statement (Form S-8 No. 333-118944) pertaining to the Ventas Executive Deferred Stock Compensation Plan and Ventas Nonemployee Director Deferred Stock Compensation Plan,

 

(9)         the Registration Statement (Form S-8 No. 333-107951) pertaining to the Ventas, Inc. 2000 Stock Option Plan for Directors,

 

(10)  the Registration Statement (Form S-8 No. 333-97251) pertaining to the Ventas, Inc. 2000 Incentive Compensation Plan,

 

(11)  the Registration Statement (Form S-8 No. 333-61552) pertaining to the Ventas, Inc. Common Stock Purchase Plan for Directors,

 

of our report dated February 23, 2015, with respect to the consolidated financial statements of AHS Medical Holdings LLC included in this Current Report on Form 8-K/A of Ventas, Inc. dated September 1, 2015.

 

 

/s/ Ernst & Young LLP

 

Nashville, Tennessee
September 1, 2015

 




Exhibit 99.1

 

CONSOLIDATED FINANCIAL STATEMENTS

 

AHS Medical Holdings LLC

Years Ended December 31, 2014 and 2013

With Report of Independent Auditors

 



 

AHS Medical Holdings LLC

 

Consolidated Financial Statements

 

Years Ended December 31, 2014 and 2013

 

Contents

 

Report of Independent Auditors

1

 

 

Audited Consolidated Financial Statements

 

 

 

Consolidated Statements of Operations

3

Consolidated Balance Sheets

4

Consolidated Statements of Cash Flows

6

Consolidated Statements of Members’ Equity

8

Notes to Consolidated Financial Statements

9

 



 

Report of Independent Auditors

 

The Board of Managers and Members

AHS Medical Holdings LLC

 

We have audited the accompanying consolidated financial statements of AHS Medical Holdings LLC, which comprise the consolidated balance sheets as of December 31, 2014 and 2013, and the related consolidated statements of operations, members’ equity, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

 

Management’s Responsibility for the Financial Statements

 

Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

 

Auditor’s Responsibility

 

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

 

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

 

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

 

1



 

Opinion

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of AHS Medical Holdings LLC at December 31, 2014 and 2013, and the consolidated results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.

 

/s/ Ernst & Young LLP

 

February 23, 2015

 

2



 

AHS Medical Holdings LLC

 

Consolidated Statements of Operations

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

 

 

(In Thousands)

 

Revenues:

 

 

 

 

 

Patient service revenue

 

$

1,902,117

 

$

1,718,781

 

Provision for doubtful accounts

 

(142,096

)

(162,709

)

Net patient service revenue

 

1,760,021

 

1,556,072

 

Premium revenue

 

193,125

 

730,239

 

Other revenue

 

73,722

 

58,066

 

Total net revenues

 

2,026,868

 

2,344,377

 

 

 

 

 

 

 

Expenses:

 

 

 

 

 

Salaries and benefits

 

859,799

 

842,400

 

Professional fees

 

241,761

 

294,192

 

Medical benefit expense

 

128,742

 

510,743

 

Supplies

 

414,428

 

397,785

 

Other operating expenses

 

200,348

 

206,653

 

Interest expense, net

 

83,402

 

88,872

 

Depreciation and amortization

 

103,253

 

105,045

 

Debt refinancing and amendment expenses

 

3,768

 

15,184

 

EHR incentive income

 

(13,713

)

(20,590

)

Gain on divestitures

 

(148,962

)

(51,512

)

Total operating expenses

 

1,872,826

 

2,388,772

 

Income (loss) from continuing operations before income taxes

 

154,042

 

(44,395

)

Income tax (benefit) expense

 

(62,517

)

89,649

 

Income (loss) from continuing operations, net

 

216,559

 

(134,044

)

Loss from discontinued operations, net

 

(293

)

(890

)

Net income (loss)

 

216,266

 

(134,934

)

Net income attributable to noncontrolling interests

 

29,756

 

22,164

 

Net income (loss) attributable to AHS Medical Holdings LLC

 

186,510

 

(157,098

)

Accrued preferred dividends

 

9,546

 

8,792

 

Net income (loss) attributable to common members

 

$

176,964

 

$

(165,890

)

 

See accompanying notes.

 

3



 

AHS Medical Holdings LLC

 

Consolidated Balance Sheets

 

 

 

December 31

 

 

 

2014

 

2013

 

 

 

(In Thousands)

 

Assets

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

172,677

 

$

144,304

 

Accounts receivable, less allowance for doubtful accounts of $122,544 in 2014 and $143,405 in 2013

 

230,915

 

206,831

 

Premiums receivable

 

 

14,658

 

Inventories

 

51,620

 

49,347

 

Prepaid expenses

 

24,913

 

36,727

 

Other current assets

 

53,944

 

67,749

 

Deferred income taxes

 

24,589

 

5,655

 

Income taxes receivable

 

591

 

1,894

 

Total current assets

 

559,249

 

527,165

 

 

 

 

 

 

 

Property and equipment, net

 

847,532

 

902,381

 

Goodwill

 

535,287

 

489,243

 

Other intangible assets, net

 

26,403

 

50,903

 

Deferred income taxes

 

37,353

 

 

Other assets

 

30,938

 

45,630

 

Total assets

 

$

2,036,762

 

$

2,015,322

 

 

4



 

AHS Medical Holdings LLC

 

Consolidated Balance Sheets (continued)

 

 

 

December 31

 

 

 

2014

 

2013

 

 

 

(In Thousands)

 

Liabilities and members’ equity

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Current installments of long-term debt

 

$

11,623

 

$

1,036,082

 

Accounts payable

 

132,129

 

158,625

 

Medical claims payable

 

8,485

 

44,983

 

Accrued salaries and benefits

 

102,884

 

88,167

 

Other accrued expenses and liabilities

 

83,031

 

68,798

 

Total current liabilities

 

338,152

 

1,396,655

 

 

 

 

 

 

 

Long-term debt, less current installments

 

862,172

 

6,621

 

Self-insured liabilities

 

87,905

 

83,736

 

Other long-term liabilities

 

7,432

 

17,838

 

Total liabilities

 

1,295,661

 

1,504,850

 

 

 

 

 

 

 

Redeemable noncontrolling interests

 

269,684

 

200,228

 

Redeemable preferred units and accrued dividends, $100 per unit price, $100 per unit redemption value; authorized, issued and outstanding: 777,498 units in 2014 and 2013

 

103,499

 

93,953

 

 

 

 

 

 

 

Members’ equity:

 

 

 

 

 

Common units: authorized: 83,168,442 units in 2014 and 2013; issued and outstanding: 75,978,314 and 75,905,862 units in 2014 and 2013, respectively

 

255,074

 

252,720

 

Investor common units: authorized, issued and outstanding: 1,554,996 units in 2014 and 2013

 

12,082

 

12,082

 

Retained earnings (deficit)

 

63,156

 

(48,511

)

Members’ equity attributable to AHS Medical Holdings LLC

 

330,312

 

216,291

 

Noncontrolling interests

 

37,606

 

 

Total members’ equity

 

367,918

 

216,291

 

Total liabilities and members’ equity

 

$

2,036,762

 

$

2,015,322

 

 

See accompanying notes.

 

5



 

AHS Medical Holdings LLC

 

Consolidated Statements of Cash Flows

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

 

 

(In Thousands)

 

Operating activities

 

 

 

 

 

Net income (loss)

 

$

216,266

 

$

(134,934

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

103,253

 

105,045

 

Gain on divestitures

 

(148,962

)

(51,512

)

Amortization of deferred financing costs and debt discounts

 

8,080

 

8,423

 

Debt refinancing and amendment expenses

 

3,768

 

15,184

 

Deferred income taxes

 

(66,330

)

87,811

 

Unit-based compensation

 

2,500

 

1,900

 

Loss from discontinued operations

 

293

 

890

 

(Income) losses in non-consolidated affiliates

 

(396

)

44

 

Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:

 

 

 

 

 

Accounts receivable

 

(20,165

)

(3,780

)

Premiums receivable

 

14,658

 

15,108

 

Inventories

 

1,016

 

178

 

Prepaid expenses and other current assets

 

22,884

 

(16,524

)

Income taxes

 

1,303

 

(102

)

Accounts payable

 

(22,104

)

23,094

 

Medical claims payable

 

(35,601

)

(20,587

)

Accrued salaries and benefits

 

13,069

 

13,957

 

Other accrued expenses and liabilities

 

21,097

 

(26,571

)

Self-insured liabilities

 

246

 

12,567

 

Net cash provided by continuing operating activities

 

114,875

 

30,191

 

Net cash provided by (used in) discontinued operating activities

 

333

 

(2,399

)

Net cash provided by operating activities

 

115,208

 

27,792

 

 

6



 

AHS Medical Holdings LLC

 

Consolidated Statements of Cash Flows (continued)

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

 

 

(In Thousands)

 

Investing activities

 

 

 

 

 

Investments in acquisitions, net of cash acquired

 

$

(45,520

)

$

(443,149

)

Purchases of property and equipment

 

(51,462

)

(56,742

)

Proceeds from divestitures, net of selling costs

 

203,493

 

54,109

 

Change in other assets and liabilities

 

12,568

 

1,315

 

Net cash provided by (used in) continuing investing activities

 

119,079

 

(444,467

)

Net cash provided by discontinued investing activities

 

1,628

 

 

Net cash provided by (used in) investing activities

 

120,707

 

(444,467

)

 

 

 

 

 

 

Financing activities

 

 

 

 

 

Proceeds from revolving line of credit

 

15,000

 

102,000

 

Proceeds from insurance financing arrangements

 

 

6,946

 

Proceeds from long-term debt

 

 

889,250

 

Payments on revolving line of credit

 

(75,000

)

(42,000

)

Payments of principal on long-term debt

 

(110,944

)

(526,412

)

Payments of principal on insurance financing arrangements

 

(4,811

)

(6,168

)

Debt refinancing and amendment costs

 

(6,900

)

(27,885

)

Distributions to noncontrolling interests

 

(24,741

)

(16,907

)

Proceeds from issuance of preferred and common units

 

 

26,092

 

Proceeds from exercise of unit options

 

694

 

170

 

Payments for minimum statutory taxes on net unit settlements

 

(840

)

(165

)

Net cash provided by (used in) financing activities

 

(207,542

)

404,921

 

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

28,373

 

(11,754

)

Cash and cash equivalents at beginning of year

 

144,304

 

156,058

 

Cash and cash equivalents at end of year

 

$

172,677

 

$

144,304

 

 

 

 

 

 

 

Supplemental cash flow information

 

 

 

 

 

Interest payments, net of capitalized interest

 

$

74,205

 

$

80,282

 

Capitalized interest

 

479

 

148

 

Income tax payments, net

 

2,510

 

1,891

 

Preferred unit dividends accrued

 

9,546

 

8,792

 

 

See accompanying notes.

 

7



 

AHS Medical Holdings LLC

 

Consolidated Statements of Members’ Equity

 

 

 

Members’ Equity Attributable to AHS Medical Holdings LLC

 

Members’ Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

Retained

 

Attributable to

 

Total

 

 

 

Common Units

 

Investor Common Units

 

Earnings

 

Noncontrolling

 

Members’

 

 

 

Units

 

Amount

 

Units

 

Amount

 

(Deficit)

 

Interests

 

Equity

 

 

 

(In Thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2012

 

75,342,134

 

$

246,761

 

1,033,194

 

$

8,028

 

$

136,868

 

$

 

$

391,657

 

Net loss attributable to AHS Medical Holdings LLC

 

 

 

 

 

(157,098

)

 

(157,098

)

Issuance of units

 

521,802

 

4,054

 

521,802

 

4,054

 

 

 

8,108

 

Exercise of unit options, net of units withheld

 

41,926

 

5

 

 

 

 

 

5

 

Unit-based compensation

 

 

1,900

 

 

 

 

 

1,900

 

Accretion of redeemable preferred units

 

 

 

 

 

(8,108

)

 

(8,108

)

Adjustment to fair value of redeemable noncontrolling interests

 

 

 

 

 

(11,381

)

 

(11,381

)

Accrual of dividends on preferred units

 

 

 

 

 

(8,792

)

 

(8,792

)

Balance at December 31, 2013

 

75,905,862

 

252,720

 

1,554,996

 

12,082

 

(48,511

)

 

216,291

 

Net income attributable to AHS Medical Holdings LLC

 

 

 

 

 

186,510

 

 

186,510

 

Exercise of unit options, net of units withheld

 

72,452

 

(146

)

 

 

 

 

(146

)

Unit-based compensation

 

 

2,500

 

 

 

 

 

2,500

 

Adjustment to fair value of redeemable noncontrolling interests

 

 

 

 

 

(65,297

)

 

(65,297

)

Acquired noncontrolling interests

 

 

 

 

 

 

36,750

 

36,750

 

Net income attributable to noncontrolling interests

 

 

 

 

 

 

856

 

856

 

Accrual of dividends on preferred units

 

 

 

 

 

(9,546

)

 

(9,546

)

Balance at December 31, 2014

 

75,978,314

 

$

255,074

 

1,554,996

 

$

12,082

 

$

63,156

 

$

37,606

 

$

367,918

 

 

See accompanying notes.

 

8



 

AHS Medical Holdings LLC

 

Notes to Consolidated Financial Statements

 

December 31, 2014

 

1. Description of the Business and Summary of Significant Accounting Policies

 

Organization and Basis of Presentation

 

AHS Medical Holdings LLC is a holding company whose affiliates operate acute care hospitals, other health care facilities, and health plans. As a Delaware Limited Liability Company (LLC), the members of the LLC are not personally liable for the debts and liabilities of the LLC in accordance to the LLC agreement, as amended and restated, and applicable statutes. The terms “Ardent” and the “Company,” as used in these financial statements, refer to AHS Medical Holdings LLC and its affiliates unless stated otherwise or indicated by context. The term “affiliates” includes direct and indirect subsidiaries of Ardent and partnerships and joint ventures in which such subsidiaries are partners. At December 31, 2014, these affiliates operated 14 acute care hospitals, including one rehabilitation hospital and two surgical hospitals, other health care facilities including physician clinics.

 

The Company operated health plans (the Health Plans) in New Mexico and Oklahoma in 2014 and 2013. The Health Plans have been divested in a series of transactions that began on August 1, 2013, and were completed on May 31, 2014. The historical results of the Health Plans, including subsequent costs related to managing retained assets and liabilities not assumed by the buyer, are included in the continuing operations of the Company’s consolidated financial statements. Refer to Note 2 for further discussion related to these transactions.

 

The Company’s integrated health care delivery system in the State of New Mexico (the Lovelace Health System) includes Lovelace Health System, Inc., which is comprised of a federally qualified health maintenance organization (the HMO), which divested of its members as of May 31, 2014, five acute care hospitals (including one rehabilitation hospital) and other health care facilities, and a network of retail pharmacies.

 

The Company’s health care delivery system in Tulsa, Oklahoma (the Hillcrest HealthCare System) includes two metropolitan acute care hospitals, a network of four regional hospitals, a surgical hospital and other health care facilities, including physician clinics.

 

Effective January 1, 2013, the Company acquired an 80% interest in Baptist St. Anthony’s Health System in Amarillo, Texas (BSA Health System), which includes a hospital and cancer center, a majority interest in a surgical hospital, a network of primary care, urgent care, and surgical clinics and various other partnerships.

 

9



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

The financial statements include the consolidated financial position and consolidated results of operations of the Company and its affiliates, which are controlled by the Company through the Company’s direct or indirect ownership of a majority interest and rights granted to the Company through certain variable interests. All intercompany balances and transactions have been eliminated in consolidation.

 

Summary of Significant Accounting Policies

 

Accounting Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

 

Reconciliation and Elimination of Intercompany Accounts and Transactions

 

The Company provided health care coverage to its Health Plans’ members for health care services that were often provided by its own hospitals and other health care facilities. This resulted in significant transactions among the Company’s affiliates that must be reconciled and eliminated for reporting of the Company’s consolidated financial statements. These transactions primarily related to health care services provided to members of the Company’s Health Plans, upon which accounts receivable and related net patient service revenue was recorded by the Company’s hospitals and other health care facilities and medical claims payable and related medical benefits expense was recorded by the Company’s Health Plans. These accounts and transactions were then eliminated upon consolidation.

 

Reclassifications

 

Certain amounts as of and for the year ended December 31, 2013 have been reclassified to conform to 2014 presentation. These reclassifications did not impact the Company’s financial position, results of operations or cash flows.

 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

Net Patient Service Revenue (and Related Discounts and Allowances)

 

Net patient service revenue is recorded on the accrual basis in the period in which services are provided. Net patient service revenue includes amounts estimated by management to be

 

10



 

reimbursable by Medicare, Medicaid and other payors under provisions of cost or prospective reimbursement formulas in effect. Amounts received are generally less than the established billing rates and the differences (contractual discounts) are reported as deductions from patient service revenue at the time the service is rendered. The effects of other arrangements for providing services at less than established rates, including certain self-pay discounts provided to uninsured patients, are also reported as deductions from patient service revenue.

 

The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex and are subject to interpretation and adjustment. The Company estimates contractual discounts on a payor-specific basis based on its interpretation of the applicable regulations or contract terms and the historical collections of each payor. However, the ultimate reimbursements may result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management. Changes in estimates related to contractual discounts affect net revenues reported in the Company’s results of operations and are recorded in the period the change in estimate occurs.

 

The Company’s facilities provide discounts on gross charges to uninsured patients under the Company’s charity and self-pay discount policy. Uninsured patients treated for nonelective care are eligible for charity care if they do not qualify for Medicaid or other federal or state assistance and have income at or below a certain income level. The estimated costs incurred by the Company to provide services to patients who qualify for charity care were $30.3 million and $19.8 million for the years ended December 31, 2014 and 2013, respectively. The Company estimates the direct and indirect costs of providing charity care by applying a cost to gross charges ratio to the gross charges associated with providing charity care to patients. Other uninsured patients receive self-pay discounts similar to those provided to many managed care plans. Because the Company does not pursue collection of amounts determined to qualify under the charity and self-pay discount policy, they are not reported in net patient service revenue or the provision for doubtful accounts. These charity and self-pay discounts totaled $273.8 million and $242.7 million in 2014 and 2013, respectively.

 

11



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

In 2014, the Company recorded an increase of $3.8 million of Medicare net patient service revenue as the estimated settlement amount for certain claims denied by Recovery Audit Contractors entities conducting reviews on behalf of the Centers for Medicare and Medicaid Services (CMS) and currently in the pending appeals process. CMS offered an administrative agreement to providers willing to withdraw their pending appeals in exchange for a timely partial payment, which was generally 68% of the claim amount, subject to certain adjustments.

 

Settlements under cost-based reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare, Medicaid and other third-party payor programs often occurs in subsequent years because of audits by the programs, rights of appeal, and the application of numerous technical provisions. Settlements are considered in the recognition of net patient service revenue on an estimated basis in the period the related services are rendered, and such amounts are subsequently adjusted in future periods as adjustments become known or as years are no longer subject to such audits and reviews. These settlements resulted in an increase to net patient service revenue of $1.5 million and $2.3 million in 2014 and 2013, respectively.

 

In 2014, a settlement agreement (the Rural Floor Settlement) was signed between the CMS, the United Statement Department of Health and Human Services, the Secretary of Health and Human Services and the Company’s hospitals. The Rural Floor Settlement was intended to resolve all claims that had been brought or could have been brought relating to CMS’ calculation of the rural floor budget neutrality adjustment for the Medicare Program’s inpatient prospective payment system that was created by the Balanced Budget Act of 1997 for federal fiscal year 1998 through and including federal fiscal year 2011. As a result of the Rural Floor Settlement, the Company recorded $4.4 million of net patient service revenue in 2014, which is included in the net adjustment to estimated settlements.

 

In 2014, the Company recorded $22.9 million as a reduction to net patient service revenue resulting from a recoupment of reimbursement previously paid to Hillcrest Medical Center in Tulsa, Oklahoma for care provided to adolescent behavioral patients. This amount is based on CMS’ determination that the Company’s child and adolescent inpatient psychiatric unit at Hillcrest Medical Center did not meet CMS reimbursement criteria for acute care. This determination by CMS resulted in this unit being unable to be reimbursed for Residential Treatment Center (RTC) and acute days. The Company disagrees with the recoupment and will appeal the CMS decision.

 

12



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

The total net adjustments to estimated settlements, including the Rural Floor Settlement and the disallowed RTC and acute days for the child and adolescent inpatient psychiatric unit, resulted in a decrease to net patient service revenue from continuing operations of $17.0 million in 2014 and an increase of $2.3 million in 2013, respectively.

 

At December 31, 2014 and 2013, the Company’s settlements under cost-based reimbursements with third-party payors were a net payable of $23.3 million and $12.4 million, respectively, of which a receivable of $14.4 million and $3.6 million, respectively, was included in other current assets and a payable of $37.7 million and $16.0 million, respectively, was included in other accrued expenses and liabilities in the consolidated balance sheets.

 

Final determination of amounts earned under prospective payment and cost-based reimbursement activities is subject to review by appropriate governmental authorities or their agents. In the opinion of the Company’s management, adequate provision has been made for any adjustments that may result from such reviews.

 

Provision for Doubtful Accounts (and Related Allowance for Doubtful Accounts)

 

The collection of accounts receivable, primarily from Medicare, Medicaid, managed care payors, other third-party payors, and patients, is critical to the Company’s operating performance. The Company’s primary collection risk that could result in bad debt relates to uninsured patient accounts and patient accounts whereby the primary insurance carrier has paid the amounts covered by the applicable agreement but the portion of the amount that is the patient’s responsibility (primarily deductibles and co-payments) remains outstanding. The Company’s collection procedures are followed until such time that management determines the account is uncollectible, at which time the account is written off. The Company routinely monitors, at the market level, its accounts receivable balances and utilizes historical collection experience to support the basis for its estimates of the allowance for doubtful accounts. Significant changes in payor mix or business office operations could have a significant impact on the Company’s results of operations and cash flows. The provision for doubtful accounts and the allowance for doubtful accounts relate primarily to self-pay amounts due from patients.

 

The Company has determined, based on an assessment at the market level, that services are provided prior to assessing the patient’s ability to pay and as such, the entire provision for bad debts is recorded as a deduction from patient service revenue in the accompanying statements of operations.

 

13



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

A summary of the Company’s allowance for doubtful accounts activity is as follows:

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Balance at January 1

 

$

143,405

 

$

120,366

 

Additions charged to provision for doubtful accounts

 

142,096

 

162,709

 

Accounts written off, net of recoveries and other

 

(162,957

)

(139,670

)

Balance at December 31

 

$

122,544

 

$

143,405

 

 

The change in expense and write-offs relate to an increase in self pay and charity discounts as well as the timing of write-offs.

 

Oklahoma Hospital Provider Fee

 

In January 2012, CMS approved the State of Oklahoma’s Supplemental Hospital Offset Payment Program (SHOPP) with an effective date of July 1, 2011. The SHOPP program created a hospital provider fee assessment on all nonexempt Oklahoma hospitals. Similar to Medicaid programs in other states, revenues from this assessment are used to fund certain SoonerCare Medicaid programs and secure additional matching Medicaid funds from the federal government. The SHOPP funds are paid to Oklahoma hospitals based on their respective health care services provided to Medicaid patients.

 

In 2014 and 2013, the Company recorded net patient service revenue of $49.8 million and $42.5 million, respectively and other operating expense of $20.7 million and $16.7 million, respectively, related to the SHOPP program, resulting in $29.2 million and $25.8 million, respectively, of income from continuing operations before income taxes.

 

14



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

Premium Revenue (and Related Premiums Receivable and Unearned Premiums)

 

Through May 31, 2014 (the date of the sale of the remainder of the health plan business — refer to Note 2 for further discussion on this divestiture), premium revenue for coverage of health care services provided by the Health Plans was recognized as revenue over the period in which enrollees were entitled to medical care. An allowance was established at December 31, 2013, for retroactive premium adjustments, as well as for doubtful accounts and other potential charges.

 

Premiums collected in advance were deferred and recorded as unearned premiums. Premiums receivable and the related allowance for doubtful accounts and retroactive adjustments were recorded on an accrual basis to report the receivables at their net realizable value.

 

The Company’s Medicare contracts were complex and subject to interpretation and retroactive adjustment. The Health Plans’ premium revenue earned pursuant to certain Medicare contracts was subject to adjustment based on certain health factors of the enrollees pursuant to CMS’ risk adjusted payment methodology. Accordingly, the Health Plans collected and periodically reported diagnosis code information to CMS. CMS periodically adjusted risk-adjusted payments during the year based on the diagnosis code submissions, with a final retroactive adjustment determined in the following year. Estimates of the risk-adjusted settlement were recorded based on the submissions of diagnosis code information and adjusted to actual amounts when the final settlement was known.

 

Medicare Part D capitation payments received from CMS included direct subsidy payments, low income subsidy payments, and reinsurance subsidy payments. Direct subsidy payments were recorded as premium revenue in the month in which the members were entitled to receive pharmacy benefits, except for any calculated risk corridor liability due to CMS, which was excluded from premium revenue as a return premium under a retrospectively rated contract. Low income subsidy payments and reinsurance subsidy payments were not included in premium revenue, and related claims incurred for these coverages were excluded from the Company’s medical benefit expense.

 

15



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

The Company’s Medicaid contracts were complex and subject to interpretation and retroactive adjustment. The Health Plans’ premium revenue earned pursuant to its Medicaid contracts was subject to certain maximum profit and minimum medical loss ratio requirements as defined in the respective contracts. At December 31, 2013, the Company established an allowance for premiums received in excess of these requirements. No such allowance at December 31, 2014.

 

Final determination of amounts earned under Medicare and Medicaid contracts is subject to review by appropriate governmental authorities or their agents. Changes in estimates related to retroactive premium adjustments affect premium revenues reported in the Company’s results of operations and are recorded in the period the change in estimate occurs.

 

Other Revenues

 

Other revenues consist primarily of retail pharmacy and cafeteria sales as well as rental and miscellaneous income within the Company’s hospitals and other health care facilities and provider network access fees and medical management services provided by the Health Plans, all of which are recognized as services are provided or goods are sold.

 

Medical Benefit Expense (and Related Medical Claims Payable)

 

Accrued medical claims are estimates of payments to be made under the health coverage plans of the Health Plans for reported claims and for claims incurred but not yet reported. Management employs standard actuarial methods to estimate the liability for medical claims payable and utilizes data developed from historical trends resulting in a best estimate approach. The estimates include assumptions related to the effects of payment patterns, benefit changes, medical trends, seasonality and other relevant factors such as catastrophic claims incidence. Other normal actuarial considerations are also considered in estimating the medical claims payable. These considerations include comparisons of current and prior bed day and admissions data to gauge the impact of changes in these metrics over time, retrospective comparisons of the actual claim payments to prior period estimates, and the relative change in claims inventory over recent months.

 

When estimates change, the Company records the adjustment to medical benefit expense in the period the change in estimate occurs. In addition, the Company accrues administrative expenses associated with those unpaid health claims that are in the process of settlement as well as those that have been incurred but not yet reported. This accrual is based on the historical relationship between claims processing expenses and incurred claims.

 

16



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

An analysis is performed and an accrual is recorded when it is probable that expected future health care costs and administrative expenses under existing contracts will exceed anticipated future premiums and insurance recoveries on those contracts. At December 31, 2014, no such accruals for loss contracts were necessary due to the finalization of the divestiture of the Health Plans on May 31, 2014. At December 31, 2013, the Company recorded an accrual of $3.8 million for a premium deficiency reserve in medical claims payable.

 

Noncontrolling Interests

 

The financial statements include the financial position and results of operations of BSA Health System, Tulsa Spine & Specialty Hospital and Bailey Medical Center in which the Company owns less than 100% but maintains a controlling interest. Additionally, the Company acquired controlling interests in Tulsa Spine & Specialty Hospital and BSA Health System in 2014 and 2013, respectively. Refer to Note 2 for further information on the Company’s acquired noncontrolling interests.

 

A summary of these entities is as follows (in thousands):

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Total assets

 

$

864,231

 

$

761,647

 

Total liabilities

 

165,136

 

153,016

 

 

 

 

 

 

 

Income from continuing operations before income taxes

 

77,251

 

46,065

 

 

For the BSA Health System, the noncontrolling interest holders have a right to sell (put) their member units to the Company (and the Company has an obligation to purchase the member units) upon the occurrence of certain events or circumstances. The option period commences on the earliest to occur of (i) the fifth anniversary date of the BSA Health System’s LLC agreement, (ii) the determination by the noncontrolling interests that its continued ownership in the Company will detrimentally affect the noncontrolling interests to continue status as a tax-exempt organization, (iii) the expiration or termination of the management agreement, or (iv) a change in control or certain legal proceedings. This put option is to be settled in cash at fair market value.

 

17



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

Additionally, the Company has an option to purchase (call) the noncontrolling interest holders’ member units for the BSA Health System commencing on the earlier to occur of (i) the date that the sharing percentage of the noncontrolling interests is less than 20%, but not before the fifth anniversary of the BSA Health System’s LLC agreement or (ii) the expiration or termination of the management agreement. This call option is to be settled in cash at fair market value.

 

In accordance with Accounting Standards Codification (ASC) 810, Consolidation, noncontrolling interests are considered to be equity holders in the consolidated company, pursuant to which noncontrolling interests are classified as part of equity, unless the noncontrolling interests are redeemable. Due to the redemptive features associated with the noncontrolling interests for the BSA Health System, this balance is classified outside the permanent equity section of the Company’s consolidated balance sheets.

 

Earnings or losses attributable to the noncontrolling interests are presented separately in the consolidated statements of operations.

 

The components of redeemable noncontrolling interests are as follows (in thousands):

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Redeemable noncontrolling interests at January 1

 

$

200,228

 

$

 

Acquisition

 

 

183,590

 

Net income attributable to redeemable noncontrolling interests

 

28,900

 

22,164

 

Distributions

 

(24,741

)

(16,907

)

Change in fair value

 

65,297

 

11,381

 

Redeemable noncontrolling interests at December 31

 

$

269,684

 

$

200,228

 

 

Changes in the fair value of the Company’s redeemable noncontrolling interests are recognized as adjustments to the Company’s consolidated members’ equity.

 

18



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

Goodwill and Other Intangible Assets

 

Goodwill represents the excess of costs over fair value of assets of businesses acquired. In accordance with ASC 350, Intangibles — Goodwill and Other, goodwill and intangible assets acquired in a purchase business combination and determined to have an indefinite useful life are not amortized, but are subject to annual impairment tests. The Company acquired businesses resulting in goodwill of $71.5 million in 2014 and $320.8 million in 2013. On a quantitative and qualitative basis, the Company compares the fair value of the reporting units to their carrying amounts on at least an annual basis to determine if there is potential impairment. If the fair value is less than carrying value, the fair value of the reporting unit is assigned to its respective assets and liabilities, including goodwill. An impairment charge is recorded if the implied fair value of goodwill is determined to be less than its carrying value. ASC 350 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment in accordance with ASC 360, Property, Plant, and Equipment. There were no goodwill or other intangible impairment charges in 2014 and 2013.

 

Risk Management and Self-Insured Liabilities

 

The Company maintains claims-made commercial insurance related to professional risks and occurrence-based commercial insurance related to workers’ compensation and general liability risks. The Company provides an accrual for actual claims reported but not paid and actuarially determined estimates of claims incurred but not reported. When estimates change, the Company records the adjustment in the period the change in estimate occurs. In addition, the Company accrues administrative expenses associated with those unpaid claims that are in the process of settlement as well as those that have been incurred but not yet reported. This accrual is based on the historical relationship between claims processing expenses and incurred claims.

 

19



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

Unit-Based Compensation

 

The Company, from time to time, grants options for a fixed number of common units to employees. Unit options are granted with an exercise price equal to or above the units’ estimated fair value at the date of grant. The units’ estimated fair value is estimated based on recent investments by investors and periodic valuations performed by valuation professionals. ASC 718, Compensation — Stock Compensation, requires the Company to recognize compensation expense in an amount equal to the fair value of unit options granted over their applicable vesting period. The Company recorded unit-based compensation of $2.5 million and $1.9 million in 2014 and 2013, respectively, for unit options granted or modified after the adoption of the provisions in ASC 718 on October 1, 2005.

 

The fair value of each option grant is estimated on the date of grant using a Black-Scholes option pricing model. The weighted average assumptions used for grants subsequent to the adoption of the provisions in ASC 718 are as follows:

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Risk-free investment interest rate

 

0.7

%

0.8

%

Expected life in years

 

4.0

 

4.0

 

Expected dividend yield

 

 

 

Expected volatility

 

40.0

%

45.0

%

 

20



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

Electronic Health Record Incentive Income

 

The American Recovery and Reinvestment Act of 2009 provides for Medicare and Medicaid incentive payments beginning in 2012 for eligible hospitals and professionals that adopt and meaningfully use certified electronic health record (EHR) technology. In 2014 and 2013, the Company recognized EHR incentive income related to the Medicare and Medicaid incentive payments. For Medicaid EHR incentive payments, recognition occurs at the time meaningful use criteria are met since Medicaid payments for the states in which the Company operates are based upon historical cost reports with no subsequent payment adjustment. For Medicare EHR incentive payments, recognition is deferred until the end of the Medicare federal fiscal year during which EHR meaningful use was demonstrated. The related income from the combined Medicare and Medicaid attestations of EHR technology was $13.7 million and $20.6 million in 2014 and 2013, respectively, and is presented as EHR incentive income in the consolidated statements of operations.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of all highly liquid investments with a maturity of 90 days or less when purchased.

 

Inventories

 

Inventories consist primarily of hospital supplies and pharmaceuticals and are stated at the lower of cost (first-in, first-out method) or market.

 

Property and Equipment

 

Property and equipment additions are stated at cost. Routine maintenance and repairs are charged to expense as incurred. Expenditures that increase values, change capacities or extend useful lives are capitalized. Depreciation is computed by applying the straight-line method over the lesser of the estimated useful lives of the assets or lease term, ranging generally from five to forty years for buildings and improvements, one to twenty years for equipment and three to ten years for leasehold improvements.

 

21



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

Other Assets

 

Other assets consist primarily of deferred financing costs, medical malpractice and workers’ compensation insurance receivables, and restricted cash and investments. Deferred financing costs are deferred and amortized over the life of the related debt under the effective interest method.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities, with the primary differences related to the allowance for doubtful accounts, accrued liabilities, depreciation methods and periods, and deferred cost amortization methods.

 

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a difference in estimated and actual tax rates is recognized in income in the period that includes the enactment date. The Company identifies deferred tax assets that more likely than not, based on the available evidence, will be unrealizable in future periods and records a valuation allowance accordingly. Refer to Note 8 for further discussion on income taxes.

 

Federal and state tax laws are complex and the Company’s tax positions may be subject to interpretation and adjustment by federal and state taxing authorities. The Company accounts for uncertain tax positions in accordance with ASC 740, Income Taxes, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions that meet the more-likely-than-not recognition threshold may be recognized. The final outcome of audits by federal and state taxing authorities may have a significant effect on the financial position and results of operations of the Company.

 

22



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

Concentrations of Credit Risk

 

Patient accounts receivable is the Company’s primary concentration of credit risk, which consists of amounts owed by various governmental agencies, managed care payors, commercial insurance companies, employers and patients. The Company manages its patient accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for uncollectible amounts. The number of patients and payors limits concentration of credit risk from any one payor.

 

The composition of the Company’s accounts receivable and net patient service revenue is as follows ($ in thousands):

 

 

 

Accounts Receivable

 

Net Patient Service Revenue

 

 

 

Year Ended December 31

 

Year Ended December 31

 

 

 

2014

 

2013

 

2014

 

2013

 

 

 

 

 

 

 

 

 

 

 

Medicare

 

$

67,889

 

$

52,535

 

$

642,143

 

$

578,859

 

Medicaid

 

21,244

 

21,510

 

190,770

 

149,383

 

Other Managed care

 

115,688

 

112,516

 

868,272

 

767,143

 

Self-pay

 

11,546

 

15,926

 

14,478

 

20,530

 

Other

 

14,548

 

4,344

 

44,358

 

40,157

 

Total

 

$

230,915

 

$

206,831

 

$

1,760,021

 

$

1,556,072

 

 

Self-pay receivables in the chart above include uninsured patients as well as co-payments and deductibles. Other includes workers’ compensation, motor and vehicle accident insurance and other similar payors.

 

The Health Plans had certain contracts with CMS and New Mexico to provide health care services to Medicare and Medicaid beneficiaries under the Medicare Advantage and Salud! programs, respectively. Medicare-related programs represented 53.3% and 41.8% of premium revenue in 2014 and 2013, respectively. There was no premium revenue from the Salud! programs in 2014. In 2013, the Salud! programs represented 19.9% of premium revenue.

 

At December 31, 2014, there were no outstanding premiums receivables. At December 31, 2013, premiums receivable includes amounts due from one major federal employer group representing 36.3% of total net premiums receivable. This group represented 15.5% and 9.5% of premium revenue in 2014 and 2013, respectively.

 

23



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

Market Risks

 

The Company’s total net revenue by market from continuing operations in 2014 and 2013 are as follows:

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Lovelace Health System

 

35.1

%

48.0

%

Hillcrest HealthCare System

 

38.9

 

31.8

 

Baptist St. Anthony’s Health System

 

26.0

 

20.2

 

Total

 

100.0

%

100.0

%

 

The Company’s cash flows and results of operations could be significantly and adversely impacted by adverse economic, legislative or other factors in these markets.

 

Fair Value of Financial Instruments

 

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value because of the short-term nature of these items.

 

24



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

The following table summarizes the Company’s assets and liabilities at fair value at December 31, 2014 and 2013 (in thousands):

 

 

 

Fair
Value

 

Level 1

 

Level 2

 

Level 3

 

December 31, 2014

 

 

 

 

 

 

 

 

 

U.S. Treasury notes

 

$

532

 

$

532

 

$

 

$

 

Term loan debt

 

783,224

 

 

783,224

 

 

Revolving credit facility

 

 

 

 

 

Subordinated debt

 

90,947

 

 

 

90,947

 

Redeemable noncontrolling interests

 

269,684

 

 

 

269,684

 

 

 

 

 

 

 

 

 

 

 

December 31, 2013

 

 

 

 

 

 

 

 

 

U.S. Treasury notes

 

$

532

 

$

532

 

$

 

$

 

Term loan debt

 

897,169

 

 

897,169

 

 

Revolving credit facility

 

60,000

 

 

 

60,000

 

Subordinated debt and other debt

 

90,947

 

 

 

90,947

 

Redeemable noncontrolling interests

 

200,228

 

 

 

200,228

 

 

In 2014, the Company repaid its revolving credit facility. Refer to Note 7 for further discussion of this payment. Additionally, refer to Note 1 for a rollforward of redeemable noncontrolling interests.

 

In general, fair values determined by Level 1 inputs utilize quoted prices in active markets for identical assets. Fair values determined by Level 2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset, and include situations where there is little, if any, market activity for the asset. Ardent determines its term loan fair value with Level 2 inputs and noncontrolling interests with Level 3 inputs.

 

25



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

Risk Pool Assessments

 

The Company is a member of the New Mexico Medical Insurance Pool and the New Mexico Health Insurance Alliance, which are risk pools for individuals who are unable to obtain health insurance on a voluntary basis. Pool members share in operating results of the pools proportionate to their share of health insurance premiums written. The Company expenses risk pool assessments in the year the related premiums are recorded, and accrues for anticipated assessments based on historical experience. There were no outstanding assessments at December 31, 2014. At December 31, 2013, the Company accrued anticipated assessments of $1.5 million, which are included in other accrued expenses and liabilities in the consolidated balance sheets. The Company also receives credits on premium taxes for a portion of pool assessments. The Company accrues these credits as the related assessments are accrued.

 

Recently Issued Accounting Pronouncements

 

In July 2011, the Financial Accounting Standards Board issued Accounting Standard Update No. 2011-06, Other Expenses (Topic 720): Fees Paid to the Federal Government by Health Insurers (ASU 2011-06). ASU 2011-06 provides authoritative guidance to the recognition and income statement reporting of the mandated health insurer fee to be paid to the federal government by health insurers, as part of the Patient Protection and Affordable Care Act. The health insurer fee is based on a company’s share of the industry’s net premiums written during the preceding calendar year and is payable on September 30 of each year. The Company adopted ASU 2011-06 for the year beginning January 1, 2014. For the year ended December 31, 2014, the Company recorded $5.6 million of other operating expenses related to the health insurer fees. All amounts were paid in 2014 and there are no outstanding payables at December 31, 2014. Due to the divestiture of the Company’s health plan operations, ASU 2011-06 will not significantly impact the Company’s financial position, results of operations or cash flows for future years. Refer to Note 2 for further discussion related to the divestiture of the Health Plans.

 

26



 

2. Acquisitions and Divestitures

 

Acquisitions

 

Acquisitions are accounted for using the acquisition method of accounting prescribed by ASC 805, Business Combinations, and the results of operations are included in the consolidated statements of operations from the respective dates of acquisition. The purchase prices of these transactions are allocated to the assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition and can be subject to change during the 12 months subsequent to the acquisition date due to settling amounts related to purchased working capital and final determination of fair value estimates. All goodwill resulting from the Company’s acquisitions is deductible for federal income tax purposes.

 

Effective December 1, 2014, the Company acquired a 51% controlling interest in a surgical hospital in Tulsa, Oklahoma, for $38.2 million. This transaction resulted in goodwill of $66.4 million. Based on the Company’s economic interest and its rights under the management agreement with the hospital, the Company has control of the joint venture’s operations and as result, it is consolidated into the Company’s financial statements.

 

In 2014, the Company also completed individually immaterial acquisitions of certain assets and operations for a combined $7.3 million. These transactions resulted in goodwill of $5.1 million.

 

Effective January 1, 2013, the Company acquired an 80% interest in Baptist St. Anthony’s Health System, which includes a 445-bed hospital and cancer center, an interest in a 41-bed surgical hospital, a network of primary care, urgent care, and surgical clinics and various other partnerships, in Amarillo, Texas for $443.1 million, net of cash acquired. The purchase price for the Baptist St. Anthony’s Health System acquisition was paid in cash and was financed, in part, with proceeds from the issuance of additional senior secured debt, preferred and common units and with cash on hand. The transaction resulted in goodwill of $320.8 million. Based on the Company’s economic interest and rights under the management agreement with Baptist St. Anthony’s Health System, the Company has control of the joint venture’s operations and as a result, it is consolidated into the Company’s financial statements.

 

2. Acquisitions and Divestitures (continued)

 

The 2014 acquisitions, which were purchased with cash on hand, strengthened the presence and market share within the Company’s existing markets. The 2013 acquisition provided the Company a successful brand in a new market while reducing the Company’s geographical and market risks.

 

27



 

The table below summarizes the allocations of the purchase price for the aforementioned acquisition transactions (in thousands; 2014 balance are preliminary subject to customary adjustments):

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

Net assets acquired:

 

 

 

 

 

Accounts receivable

 

$

6,260

 

$

51,783

 

Inventories

 

3,292

 

6,831

 

Prepaid expenses and other current assets

 

1,564

 

3,584

 

Property and equipment

 

7,214

 

266,659

 

Goodwill

 

71,517

 

320,798

 

Other intangible assets — trade name

 

 

24,600

 

Other current liabilities

 

(5,698

)

(39,989

)

Noncontrolling interests

 

(36,750

)

(183,590

)

Debt, capital leases, and other long-term liabilities

 

(1,879

)

(7,527

)

Net assets acquired, net of cash

 

$

45,520

 

$

443,149

 

 

Divestitures of Discontinued Operations

 

Effective January 8, 2014, the Company sold its home health operations in Tulsa, Oklahoma for net proceeds of $1.6 million, resulting in a gain of $1.5 million. Accordingly, operating results of these home health operations are reported as discontinued operations for all periods presented. These operations resulted in a loss from discontinued operations of $1.3 million and $907,000 in 2014 and 2013, respectively.

 

28



 

2. Acquisitions and Divestitures (continued)

 

The components of discontinued operations are as follows (in thousands):

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Net revenues from operations

 

$

(259

)

$

6,411

 

Total from discontinued operations

 

(259

)

6,411

 

 

 

 

 

 

 

Salaries and benefits

 

1,017

 

5,738

 

Professional fees

 

61

 

682

 

Supplies

 

18

 

221

 

Other operating expenses

 

435

 

660

 

Gain on divestitures

 

(1,497

)

 

Total operating expenses

 

34

 

7,301

 

Loss from discontinued operations, net

 

$

(293

)

$

(890

)

 

Other Divestitures

 

The results of operations of the following divestitures are classified in continuing operations in accordance with ASC 205, Presentation of Financial Statements, because the divestitures do not meet the criteria for classification as discontinued operations.

 

Effective May 31, 2014, the Company sold its remaining health plan operations to an affiliate of Blue Cross Blue Shield of New Mexico for net proceeds of $199.6 million with an additional $10.0 million remaining in escrow until November 30, 2015. The health plan operations sold in this transaction included approximately 95,000 Medicare and commercial members, including approximately 74,000 fully insured members. The transaction resulted in a gain of $148.5 million. A portion of the proceeds from the sale was used to pay down $100.0 million on the Company’s term loans as well as repay $75.0 million outstanding on the revolving line of credit. Refer to Note 7 for further discussion related to these debt payments.

 

Effective December 31, 2013, the Company sold the assets and operations of Oklahoma Health Plan, a federally qualified health maintenance organization, to Health Care Service Corporation for net proceeds of $8.0 million, of which $3.2 million was part of a final settlement in 2014. The transaction resulted in a gain of $6.4 million.

 

2. Acquisitions and Divestitures (continued)

 

Effective August 1, 2013, the Company sold its Health Plans’ Medicaid contract for the New Mexico Salud! Program, which served approximately 84,000 members, to Molina Healthcare of New Mexico, a subsidiary of Molina Healthcare, Inc., for net proceeds of $51.6 million, of

 

29



 

which $600,000 was part of a final settlement in 2014. The transaction resulted in a gain of $45.5 million.

 

The reconciliation of the gain on divestitures is as follows (in thousands):

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

Consideration received:

 

 

 

 

 

Cash proceeds from divestitures, net of selling costs paid

 

$

203,493

 

$

55,781

 

Receivable for additional expected consideration

 

10,000

 

3,121

 

 

 

 

 

 

 

Net assets sold:

 

 

 

 

 

Cash and accounts receivable

 

3,408

 

1,969

 

Prepaid expenses

 

388

 

500

 

Property and equipment

 

11,366

 

30

 

Goodwill

 

25,473

 

6,041

 

Intangible assets

 

25,335

 

 

Accounts payable

 

(150

)

 

Medical claims payable

 

(897

)

 

Other current liabilities

 

(392

)

(1,150

)

Net assets sold

 

64,531

 

7,390

 

Gain on divestitures

 

$

(148,962

)

$

(51,512

)

 

30



 

3. Medical Claims Payable

 

When estimates in the Company’s medical claims payable change, the Company records the adjustment to medical benefit expense in the period the change in estimate occurs. Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled. Liabilities are regularly reviewed and re-estimated as information regarding actual claims payments becomes known. This information is compared to the originally established liability.

 

The following table summarizes the changes in medical claims payable (in thousands):

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Balance at January 1

 

$

44,983

 

$

66,720

 

Incurred related to:

 

 

 

 

 

Current year

 

135,205

 

498,316

 

Prior years

 

(6,463

)

12,427

 

 

 

128,742

 

510,743

 

Paid related to:

 

 

 

 

 

Current year

 

126,720

 

452,657

 

Prior years

 

38,520

 

78,673

 

 

 

165,240

 

531,330

 

 

 

 

 

 

 

Divested

 

 

(1,150

)

 

 

 

 

 

 

Balance at December 31

 

$

8,485

 

$

44,983

 

 

As reflected in the table above, medical benefit expense includes a 2014 decrease in medical benefit expense related to prior years of $6.5 million ($4.3 million after tax) and a 2013 increase in medical benefit expense related to prior years of $12.4 million ($8.1 million after tax). The change in medical benefit expense is the result of ongoing analysis of loss development trends. Original estimates increased or decreased as additional information became known regarding individual claims.

 

31



 

4. Property and Equipment

 

Property and equipment consists of the following (in thousands):

 

 

 

December 31

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Land and improvements

 

$

76,204

 

$

76,137

 

Buildings and improvements

 

733,823

 

727,709

 

Equipment

 

541,046

 

527,654

 

Leasehold improvements

 

9,688

 

10,678

 

Construction in progress

 

26,589

 

14,639

 

 

 

1,387,350

 

1,356,817

 

Less accumulated depreciation and amortization

 

(539,818

)

(454,436

)

Property and equipment, net

 

$

847,532

 

$

902,381

 

 

Capital leases included in equipment were $12.5 million and $16.6 million at December 31, 2014 and 2013, respectively. Accumulated amortization related to capital leases was $10.3 million and $11.6 million at December 31, 2014 and 2013, respectively. Amortization expense related to capital leases was $1.9 million and $2.8 million for 2014 and 2013, respectively.

 

Software development costs included in equipment were $4.1 million and $5.2 million at December 31, 2014 and 2013, respectively. Amortization expense related to software development costs was $760,000 and $1.0 million for 2014 and 2013, respectively.

 

Depreciation and amortization of property and equipment (including capital leases and software development costs) was $102.2 million and $103.1 million in 2014 and 2013, respectively.

 

32



 

5. Goodwill and Other Intangible Assets

 

Goodwill

 

The following table summarizes the changes in the carrying amount of goodwill for the following periods (in thousands):

 

 

 

Gross

 

Accumulated
Impairment

 

Net

 

 

 

 

 

 

 

 

 

Balance at December 31, 2012

 

$

320,118

 

$

(145,632

)

$

174,486

 

Goodwill acquired

 

320,798

 

 

320,798

 

Goodwill divested

 

(6,041

)

 

(6,041

)

Balance at December 31, 2013

 

634,875

 

(145,632

)

489,243

 

Goodwill acquired

 

71,517

 

 

71,517

 

Goodwill divested

 

(25,473

)

 

(25,473

)

Balance at December 31, 2014

 

$

680,919

 

$

(145,632

)

$

535,287

 

 

In accordance with ASC 350, Intangibles — Goodwill and Other, the Company performed its annual impairment tests on goodwill and other intangible assets with indefinite useful lives at October 1, 2014 and 2013. The Company bases its estimates of fair value of reporting units on various assumptions on a quantitative and qualitative basis that are believed to be reasonable under the circumstances. Actual results may differ from these estimates, which may require a future impairment charge that could have a material adverse impact on the Company’s financial position and results of operations. The annual impairment test resulted in no impairment charges in 2014 and 2013.

 

33



 

5. Goodwill and Other Intangible Assets (continued)

 

Other Intangible Assets

 

Other intangible assets are as follows (in thousands):

 

 

 

December 31, 2014

 

December 31, 2013

 

 

 

Gross
Carrying
Amount

 

Accumulated
Amortization

 

Net
Carrying
Amount

 

Gross
Carrying
Amount

 

Accumulated
Amortization

 

Net
Carrying
Amount

 

Amortized intangible assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer relationships

 

$

 

$

 

$

 

$

35,300

 

$

(31,204

)

$

4,096

 

Provider network

 

 

 

 

1,500

 

(604

)

896

 

Non-compete

 

1,922

 

(119

)

1,803

 

622

 

(311

)

311

 

 

 

1,922

 

(119

)

1,803

 

37,422

 

(32,119

)

5,303

 

Unamortized intangible assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade name

 

24,600

 

 

24,600

 

45,600

 

 

45,600

 

 

 

$

26,522

 

$

(119

)

$

26,403

 

$

83,022

 

$

(32,119

)

$

50,903

 

 

The Company was amortizing customer relationships over approximately 12 weighted average years and its provider network over 30 weighted average years. Amortization expense for intangible assets totaled $1.1 million and $1.9 million in 2014 and 2013, respectively. The Company’s non-compete will be fully amortized by 2019.

 

Other intangible assets associated with the Health Plans such as customer relationships, provider network and trade name were written off subsequent to the sale of the remaining Health Plan business on May 31, 2014.

 

34



 

6. Other Assets

 

Direct and incremental costs related to the issuance of debt such as legal fees, printing costs, and bankers’ or underwriters’ fees, among others, are capitalized and reported as deferred financing costs. In 2013, the Company capitalized $12.6 million of financing costs associated with the Company’s 2013 senior secured credit agreement. Capitalized costs associated with the 2013 senior credit agreement are being amortized over the term of the credit agreement using the effective interest method. Refer to Note 7 for further information related to the senior secured credit agreement.

 

At December 31, 2014 and 2013, deferred financing costs were $11.7 million and $15.9 million, respectively, and were net of accumulated amortization of $7.1 million and $12.8 million, respectively. As a result of the debt payment on the Company’s senior secured credit in 2014, the Company recorded a write-off of $691,000 to deferred financing costs, which were a part of debt amendment costs. Refer to Note 7 for further information related to these debt payments.

 

Restricted cash and investments related to the Company’s Health Plans were $532,000 and $11.6 million at December 31, 2014 and 2013, respectively. U.S. Treasury Notes totaling $532,000 were on deposit with the insurance division for New Mexico at both December 31, 2014 and 2013. The Company maintained $11.0 million held in trust accounts at December 31, 2013. These balances were required pursuant to the Health Plans’ Salud! Medicaid program agreement with the New Mexico Human Services Department. Since the Company divested its Salud! Medicaid contract in August 2013, the insurance division for New Mexico returned the $11.0 million in trust accounts in 2014.

 

35



 

7. Long-Term Debt and Financing Matters

 

Long-term debt consists of the following (in thousands):

 

 

 

December 31

 

 

 

2014

 

2013

 

Term loans (interest at 6.8% for first lien and 11.0% for second lien at December 31, 2014 and interest at 6.8% for first lien and 11.0% for second lien at December 31, 2013), net of unamortized discount of $13.5 million and $13.0 million at December 31, 2014 and 2013, respectively

 

$

764,757

 

$

879,718

 

Revolving credit facility (interest at 5.6% at December 31, 2013)

 

 

60,000

 

Subordinated debt (interest at 10.2%), net of unamortized discount of $ and $1.2 million at December 31, 2014 and 2013, respectively

 

90,947

 

89,715

 

Other

 

18,091

 

13,270

 

Total debt

 

873,795

 

1,042,703

 

Less current installments

 

(11,623

)

(1,036,082

)

Long-term debt, less current installments

 

$

862,172

 

$

6,621

 

 

Senior Secured Credit Facility

 

2013 Senior Secured Credit Agreements

 

Effective January 1, 2013, the Company entered new senior secured credit agreements (2013 Credit Agreements). Under the 2013 Credit Agreements, the Company entered into a $725.0 million senior secured term loan due June 2018 and a $120.0 million revolving credit facility expiring in January 2018 under first lien facilities (together First Lien Credit Agreement) and a $175.0 million second lien term loan maturing in January 2019 (the Second Lien Credit Agreement). The Company may request up to an additional $75.0 million aggregate amount of senior secured term loans or increases in the revolving credit facility subject to certain terms and senior leverage ratio requirements. The Company recorded $15.2 million to debt refinancing expenses in the accompanying consolidated statements of operations in 2013.

 

36



 

7. Long-Term Debt and Financing Matters (continued)

 

Interest on the senior secured term loan of $725.0 million and revolving credit facility of $120.0 million of the First Lien Credit Agreement is payable at an interest rate of London Interbank Offered Rate (LIBOR) plus 5.25% with a 1.50% minimum LIBOR base applicable to the term loan only or a base rate plus 4.25%. The Company pays a commitment fee of 0.50% of the average daily unused amount of the revolving credit facility and other fees based on the LIBOR margin on outstanding letters of credit. Interest on the term loan of $175.0 million in the Second Lien Credit Agreement is payable at an interest rate of LIBOR plus 9.50% with a 1.50% minimum LIBOR base or a base rate plus 8.50%.

 

The 2013 Credit Agreements contain various financial covenants including a maximum senior leverage ratio and a capital expenditures maximum. In addition, under the 2013 Credit Agreements, the Company has to make mandatory prepayments for (i) 100% of asset sales greater than $5 million, subject to reinvestment timelines, (ii) 100% of debt issuance with carve-outs for permitted debt, (iii) 50% of net cash proceeds from any issuance of any equity interest until a maximum senior leverage ratio is met, with exceptions for issuances to sponsor or other members of the sponsor group, and (iv) a determined percentage of excess cash flow, subject to a lower percentage based upon the senior leverage ratio beginning in 2013, as defined in the 2013 Credit Agreements. The 2013 Credit Agreements also limit certain of the Company’s activities including its ability to incur additional indebtedness, declare dividends, repurchase stock, engage in mergers or acquisitions or sell assets.

 

The 2013 Credit Agreements are guaranteed by a stock pledge of all guarantor entities as well as being secured by a first and second lien on substantially all of the Company’s assets outside of Lovelace Health System, Inc. and BSA Health System, and intercompany debt owed by the guarantors.

 

There were no outstanding borrowings under the revolving credit facility at December 31, 2014, other than letters of credit that reduce the amount available under the revolving line of credit. At December 31, 2014, $113.9 million was available to the Company under the $120.0 million revolving line of credit.

 

In conjunction with the issuance of the total $725.0 million term loan, a $7.25 million discount was paid based upon a 1% discount and on the $175.0 million term loan, a $3.5 million discount was paid based upon a 2% discount. These payments were recorded as a discount to the carrying value of the term loans and will be amortized over the term of the term loans using the effective interest method.

 

7. Long-Term Debt and Financing Matters (continued)

 

Amendment to the 2013 Senior Secured Credit Agreements

 

In May 2014, the Company amended its 2013 Agreements (2014 Amendments). In addition to permitting the divestiture of its remaining Health Plan segment, the 2014 Amendments included

 

37



 

changes to certain financial covenants to exclude the health plan operations effective December 31, 2013, subject to receiving final regulatory approval from CMS by July 7, 2014, and the divestiture occurring by August 1, 2014.

 

The Company completed the sale of the remaining Health Plan on May 31, 2014. On June 5, 2014, the Company repaid a total of $175.0 million under the 2013 Senior Credit Agreement, comprised of $50.0 million of each of the first lien and second lien term loans and $75.0 million of the revolving credit facility, thereby fulfilling the terms of the 2014 Amendments. Upon payment to the first and second lien term loans, the Company has written off $1.7 million of debt discounts, which were a part of debt amendment costs. The Company was in compliance with all applicable covenants at December 31, 2014 and 2013.

 

In conjunction with the issuance of the 2014 Amendments, a $5.6 million discount was paid to the lenders. These payments were recorded as a discount to the carrying value of the term loans and are being amortized over the term of the term loans using the effective interest method. Accretion of the discount, which is included in interest expense, was $1.0 million in 2014. Additionally, the Company recorded $1.3 million of third party fees to debt amendment expenses in the accompanying consolidated statements of operations in 2014 as part of the issuance of the 2014 Amendments.

 

Reclassification of Long-Term Debt to Current Installments of Long-Term Debt

 

Prior to the sale of the Health Plans, the Company projected that it would violate terms of the 2014 Amendments during 2014 if the sale of its Health Plan did not receive final CMS approval by July 7, 2014, or the transaction had not occurred by August 1, 2014, and it had not obtained a subsequent amendment or waiver of these terms, including its financial leverage covenants. As a result of the possible future violation, the Company classified the debt from the 2013 Credit Agreements, the subordinated notes, and any other applicable debt as well as associated discounts, in current liabilities in 2013. At no time was the Company in default for a lack of cash payment to its lenders in 2013 or for subsequent periods.

 

38



 

7. Long-Term Debt and Financing Matters (continued)

 

On May 6, 2014, the Company received the necessary regulatory approval from the United States Department of Justice. The Company completed the sale on May 31, 2014 and fulfilled all compliance requirements to the 2014 Amendments.

 

Letters of Credit

 

The Company had $6.1 million and $7.3 million outstanding in letters of credit at December 31, 2014 and 2013, respectively. The letters of credit are outstanding for insurer requirements and performance guarantees and are secured by the collateral under the senior secured credit agreement.

 

Subordinated Notes

 

At December 31, 2014 and 2013, the Company had outstanding $84.2 million principal amount of 10.2% notes due 2019 to WCAS Capital Partners III, L.P., an investment fund affiliated with the Company’s controlling unit holder.

 

At December 31, 2014 and 2013, the Company also had an outstanding $6.7 million principal amount of 10.2% subordinated notes due 2019 to FFC Partners II, L.P., and FFC Executive Partners II, L.P, each an affiliate of a unit holder of the Company.

 

The common and preferred units issued with the subordinated notes were recorded as a discount and are being accreted over the term of the notes. Accretion of the discounts, which is included in interest expense, was $1.2 million and $2.0 million in 2014 and 2013, respectively.

 

Interest on the subordinated notes accrues at a rate of 10.2% per annum, except that if any interest payment is not paid in cash, an amount equal to the interest that would have accrued during the applicable interest period at an effective rate of 12.2% (instead of 10.2%) will be added to the outstanding principal amount of the subordinated notes. Interest on the subordinated notes is payable semiannually in arrears.

 

The subordinated notes may be prepaid, in whole or in part, without premium or penalty. In addition, subject to certain limitations, the subordinated notes are required to be prepaid in the event of any of the following occurring with respect to the Company: (i) change of control, (ii) initial public offering, or (iii) sale of all or substantially all of the assets.

 

39



 

7. Long-Term Debt and Financing Matters (continued)

 

The subordinated notes contain certain covenants, including covenants restricting the Company’s ability to (i) consolidate or merge with other entities, and (ii) make restricted payments. The subordinated notes are unsecured and are not guaranteed by any of the Company’s subsidiaries.

 

Under the subordination provisions of the subordinated notes, the Company may not make any payment in respect of the subordinated notes (1) for so long as a payment default under any “Senior Indebtedness” (defined as obligations under the Company’s senior secured credit facility) occurs and is continuing or (2) during the 180-day period following notice of any other default under such Senior Indebtedness, until (i) such default is cured or waived in writing or (ii) the applicable Senior Indebtedness has been paid in full in cash. Subject to certain limitations, the agent under the senior secured credit facility (on behalf of the lenders) may deliver up to two payment blockage notices during any 360-day period, but in no event will cash payments be blocked for more than 180 days during any such 360-day period.

 

Future Installments

 

Future scheduled installments of long-term debt at December 31, 2014, are as follows (in thousands):

 

2015

 

$

11,623

 

2016

 

9,653

 

2017

 

8,230

 

2018

 

639,524

 

2019 and thereafter

 

218,257

 

Total (excluding unamortized discount of $13,492)

 

$

887,287

 

 

40



 

8. Income Taxes

 

Significant components of the Company’s net deferred tax assets are as follows (in thousands):

 

 

 

December 31

 

 

 

2014

 

2013

 

Deferred tax assets:

 

 

 

 

 

Patient accounts receivable, net

 

$

19,430

 

$

26,122

 

Accrued liabilities

 

54,882

 

48,405

 

Charitable contributions

 

192

 

106

 

Insurance

 

20

 

317

 

Amortization

 

 

1,342

 

Federal net operating loss carryforward

 

18,079

 

72,222

 

State net operating loss carryforward

 

22,497

 

20,643

 

Federal tax credit carryforward

 

14,374

 

10,353

 

Total deferred tax assets

 

129,474

 

179,510

 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

Prepaid expenses

 

(2,721

)

(4,062

)

Partnership basis differences

 

(5,701

)

(4,844

)

Depreciation and amortization

 

(39,525

)

(44,932

)

Total deferred tax liabilities

 

(47,947

)

(53,838

)

Valuation allowance for deferred tax assets

 

(19,585

)

(130,060

)

Net deferred tax (liabilities) assets

 

$

61,942

 

$

(4,388

)

 

At December 31, 2014, the Company had federal and state net operating loss carryforwards of $89.8 million and $386.8 million, respectively, for income tax purposes that expire in 2015 through 2032. During 2014, the Company had no federal net operating losses expire unused and $9.9 million of state net operating losses expired unused. At December 31, 2014, the Company had a total federal tax credit carryforward of $10.5 million related to the Indian Employment Credit Program, Work Opportunity Tax Credit, and HIRE Act Retention Credit Program for income tax purposes that expires in 2025 through 2031. Additionally, the Company had an Alternative Minimum Tax Credit of $3.9 million at December 31, 2014, that will not expire. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable

 

41



 

8. Income Taxes (continued)

 

income during the periods in which those temporary differences become deductible. Management considers the positive and negative evidence from all sources including net operating loss carryback opportunities, historical operating results, prudent and feasible tax planning strategies and projections of future taxable income.

 

Based upon the analysis of positive and negative evidence, the Company recognized a tax benefit of $110.5 million in 2014 and tax expense of $113.3 million in 2013. These changes in valuation allowances are based on the Company’s assessment of the ability to realize its state and federal deferred tax assets. At December 31, 2013, the Company determined that the uncertainty regarding the completion of the sale of the Health Plans had a negative effect on future taxable earnings and full federal and state valuation allowances were warranted. The sale of the remaining business of the Health Plans was completed on May 31, 2014. At December 31, 2014, the Company determined that the negative evidence no longer affected future taxable earnings and a full federal and state valuation allowance was no longer warranted. A valuation allowance of $19.6 million remains at December 31, 2014, related to certain federal net operating losses subject to limitation on use and the majority of state deferred tax assets. Subsequently recognized tax benefit or expense relating to the valuation allowance for deferred tax assets will be reported as an income tax benefit or expense in the consolidated statements of operations.

 

Significant components of the provision (benefit) for income taxes attributable to continuing operations are as follows (in thousands):

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

Current:

 

 

 

 

 

Federal

 

$

2,196

 

$

 

State

 

1,611

 

2,029

 

Total current

 

3,807

 

2,029

 

 

 

 

 

 

 

Deferred:

 

 

 

 

 

Federal

 

(66,178

)

88,106

 

State

 

(146

)

(486

)

Total deferred

 

(66,324

)

87,620

 

Income tax expense (benefit)

 

$

(62,517

)

$

89,649

 

 

42



 

8. Income Taxes (continued)

 

The Company’s consolidated effective tax rate from continuing operations differed from the amounts computed using the federal statutory rate as set forth below (dollars in thousands):

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

 

 

Amount

 

Percent

 

Amount

 

Percent

 

 

 

 

 

 

 

 

 

 

 

Tax at federal statutory rate

 

$

53,812

 

35.0

%

$

(15,537

)

(35.0

)%

States taxes, net of federal benefits

 

952

 

0.6

 

1,004

 

2.3

 

Permanent differences

 

6,413

 

4.2

 

4,235

 

9.5

 

Noncontrolling Interests

 

(10,967

)

(7.1

)

(8,177

)

(18.4

)

Change in federal valuation allowance

 

(111,428

)

(72.1

)

111,116

 

250.3

 

Other, net

 

(1,299

)

(1.0

)

(2,992

)

(6.8

)

Income tax expense (benefit)

 

$

(62,517

)

(40.4

)%

$

89,649

 

201.9

%

 

The Company follows provisions of ASC 740, Income Taxes, regarding uncertainty in income taxes. Upon adoption of such provisions in 2009, the Company identified $2.2 million of unrecognized tax benefits. The unrecognized tax benefits are reflected as a reduction to deferred tax assets for federal and state net operating losses generated by uncertain tax deductions.

 

In 2013, the Company, with the consent of the Internal Revenue Service, changed its method of accounting for each uncertain tax position to eliminate the uncertainty regarding the tax position. At December 31, 2014 and 2013, no unrecognized tax benefits were reflected on the consolidated balance sheets as a liability in long-term liabilities and there was no reduction of the deferred tax asset related to the federal net operating loss carryforward.

 

The Company does not expect the total unrecognized benefit to change significantly in the next 12 months.

 

43



 

8. Income Taxes (continued)

 

A summary of activity of the Company’s unrecognized tax benefits is as follows (in thousands):

 

Unrecognized tax benefits at January 1, 2012

 

$

1,790

 

Decreases resulting from change in tax accounting method

 

(1,790

)

Unrecognized tax benefits at December 31, 2013

 

 

Increases resulting from tax positions in 2014

 

 

Unrecognized tax benefits at December 31, 2014

 

$

 

 

The provisions of ASC 740 allow for the classification of interest paid on an underpayment of income tax and related penalties, if applicable, as part of income tax expense, interest expense or another appropriate expense classification based on the accounting policy election of the entity. The Company has elected to continue its historical practice of classifying interest and penalties as part of interest expense.

 

The Company is not currently under any federal or state tax examination. A federal exam of 2012 was completed during 2014 with no changes to taxable income. Due to the Company’s tax attribute carryforwards, the tax years 2003 and beyond remain open to examinations by U.S. federal and state taxing authorities.

 

9. Member Units

 

Redeemable Preferred Member Units

 

At December 31, 2014, the Company had outstanding redeemable preferred member units of 777,498, which include the 2013 issuance of 260,901 redeemable preferred units as well as a 2012 issuance of 516,597 redeemable preferred units. In 2013, the Company received $26.1 million from the issuance of 260,901 redeemable preferred units, 521,802 common units and 521,802 investor common units. These preferred units were issued to existing common unit holders and certain members of management. The proceeds were used to finance the Company’s acquisitions and for general corporate purposes and were initially allocated to the redeemable preferred units and the common and investor common units on a relative fair value basis. The holders of the redeemable preferred units do not have voting rights, except as required by law.

 

44



 

9. Member Units (continued)

 

The holders of the redeemable preferred units are entitled to receive cumulative preferred dividends on each redeemable preferred unit in an amount equal of (i) 10.0% annually of the sum of $100 plus the aggregate amount of any accrued and unpaid preferred dividends, which is payable in kind semiannually in arrears, or (ii) 12.0% annually of the sum of $100 plus the aggregate amount of any accrued and unpaid preferred dividends if the Company is unable to redeem the preferred units at any time when required. The holders of the redeemable preferred units do not have voting rights, except as required by law. Upon liquidation, dissolution, or winding up of the Company, holders of the redeemable preferred units will be entitled to be paid out of the assets available for distribution to unit holders before any distribution or payment is made to any common unit holder. The amount shall be equal to the sum of $100 per unit plus the aggregate amount of any accrued and unpaid preferred dividends on such unit through the date of payment.

 

The Company is required to redeem all redeemable preferred units upon the occurrence of a triggering event defined as (i) a business combination whereby unit holders of the Company own less than 50.0% of the voting power of all outstanding equity securities of the surviving or resulting Company, (ii) sale or other disposition by the Company of all or substantially all of its assets to an independent third-party, or (iii) an initial equity public offering of the Company under the Securities Act.

 

The Company, at its option, can redeem the redeemable preferred units, in whole or in part, at any time for a price equal to $100 per unit plus the aggregate amount of any accrued and unpaid preferred dividends on such units. In accordance with applicable accounting guidance relative to redeemable equity securities, the carrying value of the redeemable preferred units was adjusted at December 31, 2014, to reflect the full $77.8 million redemption value, plus accrued dividends of $25.7 million.

 

Common and Investor Common Units

 

The 1,554,996 common units issued with the redeemable preferred units were immediately vested upon issuance and hold the same rights as other common units. The 1,554,996 investor common units vest ratably between the first and third anniversaries of the respective issuance dates. If the Company redeems the redeemable preferred units before the third anniversary of the closing date, any such investor common units that remain unvested at such time will be forfeited. At December 31, 2014 and 2013, there were 264,869 and 845,169, respectively, unvested investor common units.

 

45



 

10. Self-Insured Liabilities

 

The liabilities for professional, general, workers’ compensation, and occupational injury liability risks are based on actuarially determined estimates. Liabilities for professional, general, workers’ compensation, and occupational injury liability risks represent the estimated ultimate cost of all reported and unreported losses incurred through the respective balance sheet dates. The accruals are estimated using individual case-basis valuations and actuarial analyses.

 

At December 31, 2014, the Company maintains claims-made professional liability insurance coverage and occurrence-based general liability insurance coverage with independent third-party carriers for claims totaling up to $90.0 million per occurrence and in the aggregate, subject to a $3.0 million self-insured retention per occurrence.

 

At December 31, 2014 and 2013, the Company’s professional and general liability accrual for asserted and unasserted claims was $74.3 million and $72.9 million, respectively, of which $61.2 million and $57.9 million, respectively, were included in self-insured liabilities and $13.1 million and $15.0 million, respectively, were included in other accrued expenses and liabilities in the consolidated balance sheets. The total costs for professional and general liability insurance are based on the Company’s premiums and retention costs and were $22.2 million and $28.7 million in 2014 and 2013, respectively.

 

Excluding Oklahoma and Texas, the Company maintains workers’ compensation liability insurance with statutory limits and employer liability policy limits of $1.0 million for each occurrence from an unrelated commercial insurance carrier subject to a $250,000 deductible per occurrence. In Oklahoma, the Company is self-insured for workers’ compensation risks, but the Company purchases excess coverage from a third-party commercial insurance carrier that provides statutory limits and employer liability policy limits of $1.0 million in excess of $500,000 per occurrence. In Texas, the Company is a “non-subscriber” to workers’ compensation insurance, but instead offers an occupational injury benefit program for work-related illnesses and injuries. The Company purchases excess coverage for the occupational injury benefit program from an independent third-party carrier for claims up to $25.0 million per occurrence or $5.0 million per person, subject to a $250,000 deductible per occurrence. At December 31, 2014 and 2013, the Company’s workers’ compensation liability accrual for asserted and unasserted claims was $13.7 million and $13.2 million, respectively, of which $9.6 million and $9.2 million, respectively, were included in self-insured liabilities and $4.1 million and $4.0 million, respectively, were included in other accrued expenses for both years and liabilities in the consolidated balance sheets. The total costs for workers’ compensation liability insurance are based on the Company’s premiums and retention costs and were $4.8 million and $4.6 million in 2014 and 2013, respectively.

 

46



 

10. Self-Insured Liabilities (continued)

 

At December 31, 2014 and 2013, the Company’s occupational injury liability accrual for asserted and unasserted claims was $389,000 and $226,000, respectively, of which $153,000 and $206,000, respectively, was included in self-insured liabilities in the consolidated balance sheets. The total costs for the occupational injury liability insurance are based on the Company’s premiums and retention costs and were $236,000 and $303,000 at December 31, 2014 and 2013, respectively.

 

The Company prepays certain of its premiums related to its professional, general and occupational injury liability risks. These prepayments are financed in part through third-party finance companies. Such prepayments were $939,000 and $6.0 million at December 31, 2014 and 2013, respectively, and were included in prepaid expenses in the consolidated balance sheets. The related liabilities owed to the finance companies were $4.8 million at December 31, 2013, and were included in other accrued expenses and liabilities in the consolidated balance sheets. There was no such liability at December 31, 2014.

 

11. Employee Benefit Plans

 

Unit Incentive Plan

 

The Company maintains an option and restricted unit purchase plan (the Incentive Plan) to provide a performance incentive and to encourage unit ownership by officers, directors, consultants, and advisors of the Company, and to align the interest of such individuals with those of the Company and its members. The maximum number of options authorized under the Incentive Plan at December 31, 2014, is 10,248,358.

 

During 2014, the Company authorized a net unit settlement of 166,000 expiring unit options whereby 108,082 common units were withheld by the Company to pay for the exercise price and statutory minimum withholding of employee income taxes on the unit option exercises. In 2014, 72,452 units were issued as a result of cash exercises and this net unit settlement.

 

During 2013, the Company authorized a net unit settlement of 71,000 expiring unit options whereby 40,074 common units were withheld by the Company to pay for the exercise price and statutory minimum withholding of employee income taxes on the unit option exercises. In 2013, 41,926 units were issued as a result of cash exercises and this net unit settlement.

 

47



 

11. Employee Benefit Plans (continued)

 

Option unit activity during the periods indicated is as follows:

 

 

 

Number of
Options

 

Weighted
Average
Exercise
Price

 

 

 

 

 

 

 

Balance at December 31, 2012

 

8,128,832

 

$

5.50

 

Granted

 

1,520,000

 

7.77

 

Exercised

 

(82,000

)

3.94

 

Cancelled

 

(745,500

)

5.03

 

Balance at December 31, 2013

 

8,821,332

 

5.94

 

Granted

 

467,500

 

5.00

 

Exercised

 

(182,000

)

3.95

 

Cancelled

 

(181,500

)

5.00

 

Balance at December 31, 2014

 

8,925,332

 

$

4.19

 

 

At December 31, 2014, the range of exercise prices and weighted average remaining contractual life of outstanding options were $3.69 to $5.00 and 4.4 years, respectively. Total compensation cost related to nonvested options and the weighted-average period over which it is expected to be recognized was $1.8 million and 1.3 years, respectively.

 

Other option information is as follows:

 

 

 

Year Ended December 31

 

 

 

2014

 

2013

 

 

 

 

 

 

 

Options exercisable

 

7,042,207

 

6,260,707

 

Weighted average exercise price of options exercisable (per unit)

 

$

4.05

 

$

5.37

 

Options available for grant

 

1,103,906

 

1,230,101

 

 

48



 

11. Employee Benefit Plans (continued)

 

All options granted under the Incentive Plan expire 10 years from the date of grant. Options granted under the Incentive Plan generally vest ratably 25.0% at the end of each year of a four-year period with the exception of options granted to key employees and directors, as defined, which vest ratably over either two years (50% annually) or three years (33% annually).

 

In 2014, the Company modified existing options with a strike price of $7.75 and $7.77 to $5.00. Additionally, the Company extended the expiration date of options granted in 2004 and 2005 to 2024 and 2025, an extension of 10 years. These option modifications resulted in an additional option compensation expense of $794,000 in 2014, which is included in salaries and benefits in the accompanying consolidated statements of operations.

 

Defined Contribution Plan

 

The Company maintains a defined contribution retirement plan, the Ardent Health Services Retirement Savings Plan (the Plan). The Plan covers all employees who have attained the age of 21 and have completed ten hours of service in a three-month period. The Plan provides for a discretionary Company matching contribution. In 2014 and 2013, the employer contribution was an amount equal to 100.0% of eligible employees’ pretax contributions not to exceed a maximum of 3.0% of the eligible employees’ compensation and 50.0% of eligible employees’ pretax contributions for the next 2.0% of the eligible employees’ compensation contributed to the Plan. The Company incurred total costs related to the Plan of $13.5 million and $13.8 million in 2014 and 2013, respectively.

 

Employee Health Plan

 

The Company maintains a self-insured medical and dental plan for substantially all employees. Amounts are accrued under the Company’s medical and dental plan as the claims that give rise to them occur and the Company includes a provision for incurred but not reported claims. Incurred but not reported claims are estimated based on an average lag time and experience. Accruals are based on the estimated ultimate cost of settlement, including claim settlement expenses. The total costs of employee health coverage were $59.8 million and $59.7 million in 2014 and 2013, respectively. At December 31, 2014 and 2013, the Company had a liability of $10.8 million and $6.5 million, respectively, for this plan.

 

49



 

12. Minimum Net Worth and Dividend Restrictions

 

Statutory requirements of New Mexico require Lovelace Health System, Inc. to maintain minimum net worth of approximately 8.0% of total medical and hospital expenses, as such net worth is defined by accounting practices as prescribed or permitted by the New Mexico Office of Superintendent of Insurance. Lovelace Health System, Inc.’s net worth met this requirement at December 31, 2014 and 2013.

 

Without prior approval of its domiciliary superintendent, dividends from Lovelace Health System, Inc. to the Company are limited by the laws of New Mexico in an amount that is based on restrictions relating to minimum net worth. Within the limitations above, there are no restrictions placed on the amount that may be paid as ordinary dividends to the Company. Ordinary dividends of $24.9 million were paid to Ardent by Lovelace Health System, Inc. in 2013. There were no ordinary dividends in 2014.

 

In 2014, an extraordinary dividend of $125.0 million was declared and paid to Ardent by Lovelace Health System, Inc. The extraordinary dividend in 2014 was approved by the domiciliary superintendent and had no impact to the Company’s financial position or results of operations. There were no extraordinary dividends in 2013.

 

13. Reinsurance

 

In the ordinary course of business, the Company’s Health Plans reinsured risks for the purpose of limiting the maximum exposure on large medical claims incurred by members of its Medicaid Salud!, Medicare Advantage, Commercial HMO and PPO programs. The Health Plans entered into an agreement for reinsurance with HCC Life Insurance Company, a wholly owned subsidiary of HCC Insurance Holdings, Inc., pursuant to which the Health Plans paid a monthly premium based on an established rate per applicable member. In return for premiums paid, the Health Plans were reimbursed a percentage of costs in excess of a deductible for hospital and physician services rendered to eligible members. The Health Plans remain primarily liable for its obligation in the event that the assuming insurer is unable to meet its contractual requirements.

 

Premiums paid to HCC Life Insurance Company in 2014 and 2013 were $1.2 million and $2.5 million, respectively. These premiums are included in medical benefit expense in the consolidated statements of operations. Amounts accrued and recovered for covered charges related to 2014 and 2013 were $1.2 million and $3.7 million, respectively, and are included in medical benefit expense in the consolidated statements of operations.

 

50



 

14. Commitments and Contingencies

 

Net Patient Service Revenue

 

The Medicare and Medicaid regulations and various managed care contracts, under which the discounts from the Company’s standard charges must be calculated, are complex and are subject to interpretation and adjustment. The Company estimates contractual discounts on a payor-specific basis based on its interpretation of the applicable regulations or contract terms. However, the necessity of the services authorized and provided, and resulting reimbursements are often subject to interpretation. These interpretations may result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating continual review and assessment of the estimation process by management.

 

The final determination of amounts earned under Medicare and Medicaid programs often does not occur until fiscal years subsequent to submission of claims due to audits by the administering agency, rights of appeal and the application of numerous technical provisions. Differences between original estimates and subsequent revisions, including final settlements, are included in the results of operations of the period in which the revisions are made.

 

Litigation and Regulatory Matters

 

From time to time, claims and suits arise in the ordinary course of the Company’s business. In certain of these actions, plaintiffs request punitive or other damages against the Company that may not be covered by insurance. The Company does not believe that it is a party to any proceeding that, in management’s opinion, would have a material adverse effect on the Company’s business, financial condition, or results of operations.

 

51



 

14. Commitments and Contingencies (continued)

 

Acquisitions

 

The Company has acquired and plans to continue to acquire businesses with prior operating histories. Acquired companies may have unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations, such as billing and reimbursement, fraud and abuse and anti-kickback laws. The Company has from time to time identified certain past practices of acquired companies that do not conform to its standards. Although the Company institutes policies designed to conform such practices to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for the past activities of these acquired facilities that may later be asserted to be improper by private plaintiffs or government agencies. Although the Company generally seeks to obtain indemnification from prospective sellers covering such matters, there can be no assurance that any such matter will be covered by indemnification, or if covered, that such indemnification will be adequate to cover potential losses and fines.

 

Employment Agreements

 

Certain members of the Company’s management have entered into employment agreements with the Company. The agreements provide for minimum salary levels, participation in bonus plans and amounts payable in connection with severance of employment from the Company.

 

Operating Leases

 

The Company leases various buildings, office space and equipment under cancelable and noncancelable operating leases. Some of these leases contain renewal options at market rates at the end of the lease term. At December 31, 2014, the future minimum lease commitments under noncancelable leases (with initial or remaining lease terms in excess of one year) are as follows (in thousands):

 

2015

 

$

20,323

 

2016

 

18,358

 

2017

 

13,849

 

2018

 

10,950

 

2019

 

9,914

 

Thereafter

 

53,962

 

Total rental payments

 

$

127,356

 

 

52



 

14. Commitments and Contingencies (continued)

 

Total rent expense was $40.6 million and $40.9 million in 2014 and 2013, respectively. The aggregate future minimum sublease income is $460,000 at December 31, 2014.

 

Certain operating leases include rent increases during the initial lease term. For these leases, the Company recognizes the related rental expenses on a straight-line basis over the term of the lease, which includes any rent holiday period, and records the difference between the amounts charged to operations and amount paid as rent as a deferred rent liability.

 

15. Related-Party Transactions

 

As discussed in Note 7, the Company has $84.2 million of subordinated notes due to an affiliate of the Company’s controlling unit holder at December 31, 2013. Interest expense associated with this debt totaled $8.6 million in both 2014 and 2013.

 

As also discussed in Note 7, the Company has $6.7 million of subordinated notes due to affiliates of FFC Partners, which owns common units and redeemable preferred units of the Company, at December 31, 2013. Interest expense associated with this debt totaled $689,000 in both 2014 and 2013.

 

16. Subsequent Events

 

The Company has evaluated its financial statements and disclosures for the impact of subsequent events through February 23, 2015, the date these consolidated financial statements were available for issuance.

 

53




Exhibit 99.2

 

CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS (UNAUDITED)

 

AHS Medical Holdings LLC

Six Months Ended June 30, 2015 and 2014

 



 

AHS Medical Holdings LLC

 

Condensed Consolidated Financial Statements - Unaudited

 

Six Months Ended June 30, 2015 and 2014

 

Contents

 

Condensed Consolidated Financial Statements (Unaudited)

 

 

 

Condensed Consolidated Statements of Operations

1

Condensed Consolidated Balance Sheets

2

Condensed Consolidated Statements of Cash Flows

4

Condensed Consolidated Statements of Members’ Equity

6

Notes to Condensed Consolidated Financial Statements

7

 



 

AHS Medical Holdings LLC

 

Condensed Consolidated Statements of Operations

(Unaudited)

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

2015

 

2014

 

 

 

(In Thousands)

 

Revenues:

 

 

 

 

 

Patient service revenue

 

$

1,048,360

 

$

924,091

 

Provision for doubtful accounts

 

(65,761

)

(76,262

)

Net patient service revenue

 

982,599

 

847,829

 

Premium revenue (expense)

 

(304

)

192,353

 

Other revenue

 

28,319

 

35,276

 

Total net revenues

 

1,010,614

 

1,075,458

 

 

 

 

 

 

 

Expenses:

 

 

 

 

 

Salaries and benefits

 

460,423

 

424,683

 

Professional fees

 

121,337

 

125,160

 

Medical benefit expense

 

 

140,857

 

Supplies

 

211,767

 

199,175

 

Other operating expenses

 

97,552

 

101,551

 

Interest expense, net

 

38,129

 

44,352

 

Depreciation and amortization

 

42,775

 

53,048

 

Debt refinancing and amendment costs

 

 

6,900

 

EHR incentive income

 

(3,466

)

(5,188

)

Gain on divestitures

 

(2,491

)

(148,849

)

Total operating expenses

 

966,026

 

941,689

 

Income from continuing operations before income taxes

 

44,588

 

133,769

 

Income tax expense (benefit)

 

10,127

 

(74,991

)

Income from continuing operations, net

 

34,461

 

208,760

 

Income (loss) from discontinued operations, net

 

(9

)

90

 

Net income

 

34,452

 

208,850

 

Net income attributable to noncontrolling interests

 

16,244

 

13,479

 

Net income attributable to AHS Medical Holdings LLC

 

18,208

 

195,371

 

Accrued preferred dividends

 

5,175

 

4,617

 

Net income attributable to common members

 

$

13,033

 

$

190,754

 

 

1



 

AHS Medical Holdings LLC

 

Condensed Consolidated Balance Sheets

(Unaudited)

 

 

 

June 30,

 

December 31,

 

 

 

2015

 

2014

 

 

 

(In Thousands)

 

Assets

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

193,624

 

$

172,677

 

Accounts receivable, net of allowance for doubtful accounts of $131,125 at June 30, 2015 and $122,544 at December 31, 2014

 

236,717

 

230,915

 

Inventories

 

45,993

 

51,620

 

Prepaid expenses

 

30,726

 

24,913

 

Other current assets

 

46,158

 

53,944

 

Deferred income taxes

 

24,313

 

24,589

 

Income taxes receivable

 

151

 

591

 

Total current assets

 

577,682

 

559,249

 

 

 

 

 

 

 

Property and equipment, net

 

836,755

 

847,532

 

Goodwill

 

537,352

 

535,287

 

Other intangible assets, net

 

26,104

 

26,403

 

Deferred income taxes

 

28,895

 

37,353

 

Other assets

 

32,384

 

30,938

 

 

2



 

AHS Medical Holdings LLC

 

Condensed Consolidated Balance Sheets

(Unaudited)

 

 

 

June 30,

 

December 31,

 

 

 

2015

 

2014

 

 

 

(In Thousands)

 

Liabilities and members’ equity

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Current installments of long-term debt

 

$

11,026

 

$

11,623

 

Accounts payable

 

120,588

 

132,129

 

Medical claims payable

 

7,621

 

8,485

 

Accrued salaries and benefits

 

95,037

 

102,884

 

Other accrued expenses and liabilities

 

74,634

 

83,031

 

Total current liabilities

 

308,906

 

338,152

 

 

 

 

 

 

 

Long-term debt, less current installments

 

859,425

 

862,172

 

Self-insured liabilities

 

102,462

 

87,905

 

Other long-term liabilities

 

7,253

 

7,432

 

Total liabilities

 

1,278,046

 

1,295,661

 

 

 

 

 

 

 

Redeemable noncontrolling interests

 

270,248

 

269,684

 

Redeemable preferred units and accrued dividends, $100 per unit price, $100 per unit redemption value; authorized, issued and outstanding: 777,498 units at June 30, 2015 and December 31, 2014, respectively

 

108,674

 

103,499

 

 

 

 

 

 

 

Members’ equity:

 

 

 

 

 

Common units: authorized: 83,168,442 units at June 30, 2015 and December 31, 2014; issued and outstanding: 75,985,229 and 75,978,314 units at June 30, 2015 and December 31, 2014, respectively

 

256,330

 

255,074

 

Investor common units: authorized, issued and outstanding: 1,554,996 units at June 30, 2015 and December 31, 2014, respectively

 

12,082

 

12,082

 

Retained earnings

 

76,099

 

63,156

 

Members’ equity attributable to AHS Medical Holdings LLC

 

344,511

 

330,312

 

Noncontrolling interests

 

37,693

 

37,606

 

Total members’ equity

 

382,204

 

367,918

 

Total liabilities and members’ equity

 

$

2,039,172

 

$

2,036,762

 

 

3



 

AHS Medical Holdings LLC

 

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

2015

 

2014

 

 

 

(In Thousands)

 

Cash flows from operating activities:

 

 

 

 

 

Net income

 

$

34,452

 

$

97,420

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

(Income) loss from discontinued operations, net

 

9

 

(90

)

Depreciation and amortization

 

42,775

 

53,048

 

Gain on divestitures

 

(2,491

)

(148,849

)

Amortization of deferred financing costs and debt discounts

 

3,526

 

4,063

 

Debt refinancing and amendment costs

 

 

6,900

 

Deferred income taxes

 

8,735

 

34,133

 

Unit-based compensation

 

1,250

 

1,250

 

Equity in non-consolidated affiliates

 

(863

)

(324

)

Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:

 

 

 

 

 

Accounts receivable

 

(5,803

)

(19,790

)

Premiums receivable

 

 

4,908

 

Inventories

 

2,763

 

1,344

 

Prepaid expenses and other current assets

 

1,812

 

11,361

 

Income taxes receivable

 

440

 

1,589

 

Accounts payable

 

(11,574

)

(26,051

)

Medical claims payable

 

(864

)

(15,571

)

Accrued salaries and benefits

 

(7,847

)

(2,959

)

Other accrued expenses and liabilities

 

(8,708

)

1,573

 

Self-insured liabilities

 

9,555

 

1,614

 

Net cash provided by continuing operating activities

 

67,167

 

5,569

 

Net cash provided by discontinued operating activities

 

23

 

626

 

Net cash provided by operating activities

 

67,190

 

6,195

 

 

Continued on next page.

 

4



 

AHS Medical Holdings LLC

 

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

2015

 

2014

 

 

 

(In Thousands)

 

Cash flows from investing activities:

 

 

 

 

 

Investments in acquisitions, net of cash acquired

 

$

(1,984

)

$

(5,316

)

Purchases of property and equipment

 

(30,985

)

(14,826

)

Contribution to equity investments

 

(400

)

 

Proceeds from divestitures, net of selling costs

 

5,663

 

203,707

 

Change in other assets

 

866

 

7,375

 

Net cash provided by (used in) continuing investing activities

 

(26,840

)

190,940

 

Net cash provided by discontinued investing activities

 

 

1,628

 

Net cash provided by (used in) investing activities

 

(26,840

)

192,568

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Proceeds from revolving line of credit

 

 

15,000

 

Proceeds from insurance financing arrangements

 

5,878

 

 

Payments of principal on revolving line of credit

 

(6,207

)

(75,000

)

Payments of principal on insurance financing arrangements

 

(3,404

)

(3,217

)

Payments of principal on long-term debt

 

 

(106,584

)

Debt refinancing and amendment costs

 

 

(6,900

)

Distributions attributable to noncontrolling interests

 

(15,683

)

(10,564

)

Proceeds from exercise of unit options

 

15

 

694

 

Payments for taxes withheld on net unit settlements

 

(2

)

(840

)

Net cash used in financing activities

 

(19,403

)

(187,411

)

Net increase in cash and cash equivalents

 

20,947

 

11,352

 

Cash and cash equivalents at beginning of period

 

172,677

 

144,304

 

Cash and cash equivalents at end of period

 

$

193,624

 

$

155,656

 

 

5



 

AHS Medical Holdings LLC

 

Condensed Consolidated Statement of Members’ Equity

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Members’ Equity

 

 

 

 

 

Members’ Equity Attributable to AHS Medical Holdings LLC

 

Attributable to

 

Total

 

 

 

Common Units

 

Investor Common Units

 

Retained

 

Noncontrolling

 

Members’

 

 

 

Units

 

Amount

 

Units

 

Amount

 

Earnings

 

Interests

 

Equity

 

 

 

(In Thousands)

 

Balance at December 31, 2014

 

75,978,314

 

$

255,074

 

1,554,996

 

$

12,082

 

$

63,156

 

$

37,606

 

$

367,918

 

Net income attributable to AHS Medical Holdings LLC

 

 

 

 

 

18,208

 

 

18,208

 

Exercise of unit options

 

6,915

 

6

 

 

 

 

 

6

 

Unit-based compensation

 

 

1,250

 

 

 

 

 

1,250

 

Adjustment to fair value of redeeemable noncontrolling interests

 

 

 

 

 

(90

)

 

(90

)

Net income attributable to noncontrolling interests

 

 

 

 

 

 

1,754

 

1,754

 

Distributions to noncontrolling interests

 

 

 

 

 

 

(1,667

)

(1,667

)

Accrual of dividends on preferred units

 

 

 

 

 

(5,175

)

 

(5,175

)

Balance at June 30, 2015

 

75,985,229

 

256,330

 

1,554,996

 

12,082

 

76,099

 

37,693

 

382,204

 

 

See accompanying notes.

 

6



 

AHS Medical Holdings LLC

 

Notes to Condensed Consolidated Financial Statements (Unaudited)

 

June 30, 2015

 

1. Description of the Business and Summary of Significant Accounting Policies

 

Organization and Basis of Presentation

 

AHS Medical Holdings LLC is a holding company whose affiliates operate acute care hospitals, other health care facilities and health plans. The terms “Ardent” and the “Company,” as used in these financial statements, refer to AHS Medical Holdings LLC and its affiliates unless stated otherwise or indicated by context. The term “affiliates” includes direct and indirect subsidiaries of Ardent and partnerships and joint ventures in which such subsidiaries are partners. At June 30, 2015, these affiliates operated fourteen acute care hospitals, including one rehabilitation hospital and two surgical hospitals, other health care facilities including physician clinics.

 

The Company operated health plans (the Health Plans) in New Mexico in 2014. The Health Plans have been divested in a series of transactions that began on August 1, 2013 and were completed on May 31, 2014.  The historical results of the Health Plans, including subsequent costs related to managing retained assets and liabilities not assumed by the buyer, are included in the continuing operations of the Company’s consolidated financial statements.

 

The Company’s integrated health care delivery system in the State of New Mexico (the Lovelace Health System) includes Lovelace Health System, Inc., which is comprised of a federally qualified health maintenance organization (the HMO), which divested of its members as of May 31, 2014, five acute care hospitals (including one rehabilitation hospital) and other health care facilities, and a network of retail pharmacies.

 

The Company’s health care delivery system in Tulsa, Oklahoma (the Hillcrest HealthCare System) includes two metropolitan acute care hospitals, a network of four regional hospitals, a surgical hospital and other health care facilities, including physician clinics.

 

The Company’s health care delivery system in Amarillo, Texas is an 80% interest in Baptist St. Anthony’s Health System (BSA Health System), which includes a hospital and cancer center, a majority interest in a surgical hospital, a network of primary care, urgent care, and surgical clinics and various other partnerships.

 

7



 

1. Description of the Business and Summary of Significant Accounting Policies (continued)

 

The financial statements include the consolidated financial position and consolidated results of operations of the Company and its affiliates which are controlled by the Company through the Company’s direct or indirect ownership of a majority interest and rights granted to the Company through certain variable interests. All intercompany balances and transactions have been eliminated in consolidation.

 

Certain prior year amounts have been reclassified to conform to current year presentation.

 

In the opinion of management, the unaudited condensed consolidated financial statements reflect all material adjustments necessary for a fair presentation of the financial position and the results of operations for the periods presented. The results of operations for the period ended June 30, 2015 presented are not necessarily indicative of the expected results for the year ending December 31, 2015. The interim unaudited condensed consolidated financial statements should be read in connection with the audited consolidated financial statements as of and for the year ended December 31, 2014.

 

2. Noncontrolling Interests

 

The financial statements include the financial position and results of operations of BSA Health System, Tulsa Spine & Specialty Hospital and Bailey Medical Center in which the Company owns less than 100% but maintains a controlling interest. The Company purchased all noncontrolling interests in Bailey Medical Center in May 2015 for $1.6 million.

 

A summary of these entities is as follows (in thousands):

 

 

 

Six Months Ended June 30,

 

 

 

2015

 

2014

 

 

 

 

 

 

 

Total assets

 

868,359

 

776,276

 

Total liabilities

 

156,113

 

144,917

 

 

 

 

 

 

 

Income from continuing operations before income taxes

 

42,316

 

35,364

 

 

Subsequent to June 30, 2015, the Company purchased the noncontrolling interests in the BSA Health System.

 

8



 

3. Net Patient Service Revenue

 

Patient accounts receivable is the Company’s primary concentration of credit risk, which consists of amounts owed by various governmental agencies, managed care payors, commercial insurance companies, employers and patients. The Company manages its patient accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for uncollectible amounts. The number of patients and payors limits concentration of credit risk from any one payor.

 

The composition of the Company’s net patient service revenue is as follows:

 

 

 

Six Months Ended June 30

 

 

 

2015

 

2014

 

 

 

 

 

 

 

Medicare

 

35.6

%

38.0

%

Medicaid

 

11.3

 

10.7

 

Other Managed Care

 

49.9

 

48.1

 

Self Pay

 

0.3

 

0.4

 

Other

 

2.9

 

2.8

 

Total

 

100.0

%

100.0

%

 

9



 

4. Fair Value of Financial Instruments

 

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value because of the short-term nature of these items.

 

The following table summarizes the Company’s term loan debt and redeemable noncontrolling interests at fair value at June 30, 2015 and December 31, 2014 (dollars in thousands):

 

 

 

Fair Value

 

Level 1

 

Level 2

 

Level 3

 

June 30, 2015

 

 

 

 

 

 

 

 

 

U.S. Treasury notes

 

$

531

 

$

531

 

$

 

$

 

Term loan debt

 

$

784,938

 

$

 

$

784,938

 

$

 

Subordinated debt and other debt

 

$

90,947

 

$

 

$

 

$

90,947

 

Redeemable noncontrolling interests

 

$

270,248

 

$

 

$

 

$

270,248

 

 

 

 

 

 

 

 

 

 

 

December 31, 2014

 

 

 

 

 

 

 

 

 

U.S. Treasury notes

 

$

532

 

$

532

 

$

 

$

 

Term loan debt

 

$

783,224

 

$

 

$

783,224

 

$

 

Subordinated debt and other debt

 

$

90,947

 

$

 

$

 

$

90,947

 

Redeemable noncontrolling interests

 

$

269,684

 

$

 

$

 

$

269,684

 

 

In general, fair values determined by Level 1 inputs utilize quoted prices in active markets for identical assets. Fair values determined by Level 2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset, and include situations where there is little, if any, market activity for the asset. Ardent determines its term loan fair value with Level 2 inputs and noncontrolling interests with Level 3 inputs.

 

10



 

5. Acquisitions and Divestitures

 

Acquisitions

 

In 2015, the Company completed individually immaterial acquisitions for $2.0 million.

 

Effective December 1, 2014, the Company acquired a 51% controlling interest in a surgical hospital in Tulsa, Oklahoma, for $38.2 million. This transaction resulted in goodwill of $66.4 million. Based on the Company’s economic interest and its rights under the management agreement with the hospital, the Company has control of the joint venture’s operations and as result, it is consolidated into the Company’s financial statements.

 

In 2014, the Company also completed individually immaterial acquisitions of certain assets and operations for a combined $7.3 million. These transactions resulted in goodwill of $5.1 million.

 

Divestitures of Discontinued Operations

 

Effective January 8, 2014, the Company sold its home health operations in Tulsa, Oklahoma for net proceeds of $1.6 million, resulting in a gain of $1.5 million. Accordingly, operating results of these home health operations are reported as discontinued operations for all periods presented.

 

11



 

5. Acquisitions and Divestitures (continued)

 

Other Divestitures

 

The results of operations of the following divestitures are classified in continuing operations in accordance with ASC 205, Presentation of Financial Statements, because the divestitures do not meet the criteria for classification as discontinued operations.

 

The Company sold Lovelace Retail Pharmacy, which consists of 11 retail pharmacy locations, to the Walgreens Company. Six of the eleven retail pharmacy locations converted to Walgreens on April 8, 2015, with the remaining locations converted on May 15, 2015.  The divestiture does not include any of the Company’s hospitals, inpatient pharmacies, providers or clinics.

 

Effective May 31, 2014, the Company sold its remaining health plan operations to an affiliate of Blue Cross Blue Shield of New Mexico for net proceeds of $199.6 million with an additional $10.0 million remaining in escrow until November 30, 2015.  The health plan operations sold in this transaction included approximately 95,000 Medicare and commercial members, including approximately 74,000 fully insured members. The transaction resulted in a gain of $148.5 million. A portion of the proceeds from the sale were used to pay down $100.0 million on the Company’s term loans as well as repay $75.0 million outstanding on the revolving line of credit.

 

12



 

6. Long-Term Debt and Financing Matters

 

Long-term debt consists of the following (in thousands):

 

 

 

June 30,
2015

 

December 31,
2014

 

Term Loans (interest at 6.8% for first lien and 11.0% for second lien at June 30, 2015 and December 31, 2014), net of unamortized discount of $11.7 million and $13.5 million at June 30, 2015 and December 31, 2014, respectively

 

$

770,190

 

$

772,007

 

Subordinated debt (interest at 10.2%)

 

90,947

 

90,947

 

Other

 

9,314

 

10,841

 

Total debt

 

870,451

 

873,795

 

Less current installments

 

(11,026

)

(11,623

)

Long-term debt, less current installments

 

$

859,425

 

$

862,172

 

 

7. Commitments and Contingencies

 

Net Patient Service Revenue

 

The Medicare and Medicaid regulations and various managed care contracts, under which the discounts from the Company’s standard charges must be calculated, are complex and are subject to interpretation and adjustment. The Company estimates contractual discounts on a payor-specific basis based on its interpretation of the applicable regulations or contract terms. However, the necessity of the services authorized and provided and resulting reimbursements are often subject to interpretation. These interpretations may result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating continual review and assessment of the estimation process by management.

 

13



 

7. Commitments and Contingencies (continued)

 

The final determination of amounts earned under Medicare and Medicaid programs often does not occur until fiscal years subsequent to submission of claims due to audits by the administering agency, rights of appeal and the application of numerous technical provisions. Differences between original estimates and subsequent revisions, including final settlements, are included in the results of operations of the period in which the revisions are made.

 

Litigation and Regulatory Matters

 

From time to time, claims and suits arise in the ordinary course of the Company’s business. In certain of these actions, plaintiffs request punitive or other damages against the Company that may not be covered by insurance. The Company does not believe that it is a party to any proceeding that, in management’s opinion, would have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.

 

Acquisitions

 

The Company has acquired and plans to continue to acquire businesses with prior operating histories. Acquired companies may have unknown or contingent liabilities, including liabilities for failure to comply with health care laws and regulations, such as billing and reimbursement, fraud and abuse and anti-kickback laws. The Company has from time to time identified certain past practices of acquired companies that do not conform to its standards. Although the Company institutes policies designed to conform such practices to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for the past activities of these acquired facilities that may later be asserted to be improper by private plaintiffs or government agencies. Although the Company generally seeks to obtain indemnification from prospective sellers covering such matters, there can be no assurance that any such matter will be covered by indemnification, or if covered, that such indemnification will be adequate to cover potential losses and fines.

 

Employment Agreements

 

Certain members of the Company’s management have entered into employment agreements with the Company. The agreements provide for minimum salary levels, participation in bonus plans and amounts payable in connection with severance of employment from the Company.

 

14



 

8. Income Taxes

 

Based upon the analysis of positive and negative evidence, the Company recognized a tax benefit of $111.4 million for the six months ended June 30, 2014. These changes in valuation allowances are based on the Company’s assessment of the ability to realize its state and federal deferred tax assets. At December 31, 2013, the Company determined that the uncertainty regarding the completion of the sale of the Health Plans had a negative effect on future taxable earnings and full federal and state valuation allowances were warranted. The sale of the remaining business of the Health Plans was completed on May 31, 2014. At June 30, 2014, the Company determined that the negative evidence no longer affected future taxable earnings and a full federal and state valuation allowance was no longer warranted. Subsequently recognized tax benefit or expense relating to the valuation allowance for deferred tax assets will be reported as an income tax benefit or expense in the consolidated statements of operations.

 

9. Subsequent Events

 

The Company has evaluated its financial statements and disclosures for the impact of subsequent events through August 20, 2015, the date these consolidated financial statements were available for issuance.

 

15




Exhibit 99.3

 

VENTAS, INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of and For the Six Months Ended June 30, 2015 and For the Year Ended December 31, 2014

 

On August 4, 2015, Ventas completed its acquisition of Ardent Medical Services, Inc. (“AHS”).  Concurrent with the closing of the transaction, the Company separated AHS’s hospital operations from its owned real estate and sold the hospital operations to a newly formed and capitalized operating company (“Ardent”).  An entity controlled by Equity Group Investments acquired a majority stake in Ardent, while Ventas retained a 9.9 percent interest and AHS management retained a significant ownership stake.

 

Also, on August 17, 2015, Ventas, Inc. (“Ventas” or the “Company”), entered into a Separation and Distribution Agreement with Care Capital Properties, Inc. (“CCP”), pursuant to which the Company agreed to transfer most of its post-acute / skilled nursing facility portfolio to CCP and distribute all of the Company-owned common stock of CCP to the Company’s stockholders in a distribution intended to be tax-free to the Company’s stockholders (the “Distribution”). The Distribution was effective at 11:59 p.m., Eastern Time, on August 17, 2015 (the “Effective Time”) to the Company’s stockholders of record as of the close of business on August 10, 2015. As a result of the Distribution, CCP is now an independent public company and its common stock is listed under the symbol “CCP” on the New York Stock Exchange.

 

The following unaudited pro forma condensed consolidated financial information sets forth:

 

·             The historical consolidated financial information of Ventas as of and for the six months ended June 30, 2015, derived from Ventas’s unaudited consolidated financial statements, and the historical consolidated statement of income information of Ventas for the year ended December 31, 2014, derived from Ventas’s audited consolidated financial statements;

 

·             Pro forma adjustments to give effect of the spin-off of CCP on August 17, 2015 on Ventas’s consolidated balance sheet as of June 30, 2015, as if the spin-off occurred on June 30, 2015;

 

·             Pro forma adjustments to give effect of the AHS transaction on August 4, 2015 on Ventas’s consolidated balance sheet as of June 30, 2015, as if the transaction occurred on June 30, 2015;

 

·             Pro forma adjustments to give effect to Ventas’s other 2015 and 2014 transactions, including the 2015 acquisitions of American Realty Capital Healthcare Trust, Inc. (“HCT”) and 12 skilled nursing facilities, and other 2015 and 2014 significant debt activity, on Ventas’s consolidated statements of income for the six months ended June 30, 2015 and for the year ended December 31, 2014, as if these transactions occurred on January 1, 2014;

 

·             Pro forma adjustments to give effect of the spin-off of CCP on August 17, 2015 on Ventas’s consolidated statements of income for the six months ended June 30, 2015 and for the year ended December 31, 2014, as if the spin-off occurred on January 1, 2014; and

 

·             Pro forma adjustments to give effect of the AHS transaction on August 4, 2015 on Ventas’s consolidated statements of income for the six months ended June 30, 2015 and for the year ended December 31, 2014, as if the transaction occurred on January 1, 2014; and

 

These unaudited pro forma condensed consolidated financial statements have been prepared for informational purposes only and are based on assumptions and estimates considered appropriate by Ventas’s management; however, they are not necessarily indicative of what Ventas’s consolidated financial condition or results of operations actually would have been assuming the transactions had been consummated as of the dates indicated, nor do they purport to represent Ventas’s consolidated financial position or results of operations for future periods. These unaudited pro forma condensed consolidated

 



 

financial statements do not include the impact of any synergies that may be achieved in the transactions or any strategies that management may consider in order to continue to efficiently manage Ventas’s operations.  This pro forma condensed consolidated financial information should be read in conjunction with:

 

·             Ventas’s unaudited consolidated financial statements and the related notes thereto as of and for the six months ended June 30, 2015 included in the Company’s Quarterly Report on Form 10-Q for the quarter then ended, filed with the Securities and Exchange Commission (“SEC”) on July 27, 2015;

 



 

·             Ventas’s audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K for the year then ended, filed with the SEC on February 13, 2015;

 

·             CCP’s Predecessors combined consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2014 included in its information statement on Form 10 filed with the SEC on July 30, 2015; and

 

·             The audited consolidated financial statements of AHS Medical Holdings LLC, the 100% parent company of AHS (“AHS Medical Holdings”), as of and for the year ended December 31, 2014, included in this Current Report on Form 8-K/A; and

 

·             The unaudited condensed consolidated financial statements of AHS Medical Holdings as of and for the six months ended June 30, 2015, included in this Current Report on Form 8-K/A.

 



 

VENTAS, INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET

As of June 30, 2015

(In thousands)

 

 

 

Ventas
Historical

 

CCP Spin-Off
Adjustments
(A)

 

Pro Forma
for CCP
Spin-Off
Adjustments

 

AHS Medical
Holdings LLC
Historical (B)

 

AHS

Transaction

Adjustments

(C)

 

 

Total Pro
Forma

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net real estate investments

 

$

22,239,965

 

$

(2,597,111

)

$

19,642,854

 

$

836,755

 

$

474,226

 

(D)

$

20,953,835

 

Cash and cash equivalents

 

60,532

 

206,584

 

267,116

 

193,624

 

(164,151

)

(E)

296,589

 

Escrow deposits and restricted cash

 

193,960

 

 

193,960

 

 

 

 

193,960

 

Deferred financing costs, net

 

68,284

 

(1,642

)

66,642

 

 

8,905

 

(F)

75,547

 

Other assets

 

1,712,421

 

(159,768

)

1,552,653

 

1,008,793

 

(982,511

)

(G)

1,578,935

 

Total assets

 

$

24,275,162

 

$

(2,551,937

)

$

21,723,225

 

$

2,039,172

 

$

(663,531

)

 

$

23,098,866

 

Liabilities and equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Senior notes payable and other debt

 

$

11,507,861

 

$

(1,059,680

)

$

10,448,181

 

$

870,451

 

$

529,549

 

(H)

$

11,848,181

 

Accrued interest

 

77,631

 

 

77,631

 

 

 

 

77,631

 

Accounts payable and other liabilities

 

1,026,359

 

(205,941

)

820,418

 

407,594

 

(399,691

)

(I)

828,321

 

Deferred income taxes

 

370,161

 

 

370,161

 

 

 

 

370,161

 

Total liabilities

 

12,982,012

 

(1,265,621

)

11,716,391

 

1,278,045

 

129,858

 

 

13,124,294

 

Redeemable OP unitholder and noncontrolling interests

 

199,404

 

 

199,404

 

378,922

 

(378,922

)

 

199,404

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Ventas stockholders’ equity

 

11,027,483

 

(1,281,556

)

9,745,927

 

343,825

 

(376,087

)

 

9,713,665

 

Noncontrolling interest

 

66,263

 

(4,760

)

61,503

 

38,380

 

(38,380

)

 

61,503

 

Total equity

 

11,093,746

 

(1,286,316

)

9,807,430

 

382,205

 

(414,467

)

 

9,775,168

 

Total liabilities and equity

 

$

24,275,162

 

$

(2,551,937

)

$

21,723,225

 

$

2,039,172

 

$

(663,531

)

 

$

23,098,866

 

 

See accompanying notes to unaudited pro forma condensed consolidated financial statements.

 



 

VENTAS, INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME

For the Six Months Ended June 30, 2015

(In thousands, except per share amounts)

 

 

 

Ventas
Historical

 

Other 2015
Transactions (J)

 

Pro Forma for
Other 2015
Transactions

 

CCP Spin-Off
Adjustments (A)

 

Pro Forma for
Other 2015
Transactions
and CCP Spin-
Off Adjustments

 

AHS Medical
Holdings LLC
Historical (B)

 

AHS Transaction

Adjustments (K)

 

 

 

Total Pro Forma

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rental income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Triple-net leased

 

$

526,768

 

$

2,816

 

$

529,584

 

$

(159,152

)

$

370,432

 

$

 

$

52,500

 

(L)

 

$

422,932

 

Medical office buildings

 

277,393

 

5,004

 

282,397

 

 

282,397

 

 

 

 

 

282,397

 

 

 

804,161

 

7,820

 

811,981

 

(159,152

)

652,829

 

 

52,500

 

 

 

705,329

 

Resident fees and services

 

901,559

 

6,402

 

907,961

 

 

907,961

 

982,599

 

(982,599

)

 

 

907,961

 

Medical office building and other services revenue

 

19,951

 

 

19,951

 

 

19,951

 

 

 

 

 

19,951

 

Income from loans and investments

 

48,967

 

37

 

49,004

 

(1,725

)

47,279

 

 

 

 

 

47,279

 

Interest and other income

 

708

 

 

708

 

(63

)

645

 

28,015

 

(28,015

)

 

 

645

 

Total revenues

 

1,775,346

 

14,259

 

1,789,605

 

(160,940

)

1,628,665

 

1,010,614

 

(958,114

)

 

 

1,681,165

 

Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest

 

214,181

 

(3,774

)

210,407

 

(12,463

)

197,944

 

38,129

 

(21,791

)

(M)

 

214,282

 

Depreciation and amortization

 

496,636

 

14,430

 

511,066

 

(67,192

)

443,874

 

42,775

 

(25,028

)

(N)

 

461,621

 

Property-level operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Senior living

 

597,614

 

4,826

 

602,440

 

 

602,440

 

887,613

 

(887,613

)

 

 

602,440

 

Medical office buildings

 

85,670

 

883

 

86,553

 

 

86,553

 

 

 

 

 

86,553

 

 

 

683,284

 

5,709

 

688,993

 

 

688,993

 

887,613

 

(887,613

)

 

 

688,993

 

Medical office building services costs

 

12,682

 

 

12,682

 

 

12,682

 

 

 

 

 

12,682

 

General, administrative and professional fees

 

68,292

 

3,364

 

71,656

 

(5,000

)

66,656

 

 

 

 

 

66,656

 

Gain on extinguishment of debt, net

 

(434

)

 

(434

)

 

(434

)

 

 

 

 

(434

)

Merger-related expenses and deal costs

 

49,757

 

 

49,757

 

(3,755

)

46,002

 

 

 

 

 

46,002

 

Other

 

10,387

 

 

10,387

 

(1,019

)

9,368

 

 

 

 

 

9,368

 

Total expenses

 

1,534,785

 

19,729

 

1,554,514

 

(89,429

)

1,465,085

 

968,517

 

(934,432

)

 

 

1,499,170

 

Income (loss) before loss from unconsolidated entities, income taxes, discontinued operations, real estate dispositions and noncontrolling interest

 

240,561

 

(5,470

)

235,091

 

(71,511

)

163,580

 

42,097

 

(23,682

)

 

 

181,995

 

(Loss) income from unconsolidated entities

 

(242

)

 

(242

)

 

(242

)

 

1,500

 

(O)

 

1,258

 

Income tax benefit

 

17,039

 

2,262

 

19,301

 

 

19,301

 

(10,127

)

10,127

 

 

 

19,301

 

Income (loss) from continuing operations

 

257,358

 

(3,208

)

254,150

 

(71,511

)

182,639

 

31,970

 

(12,055

)

 

 

202,554

 

Gain on real estate dispositions

 

14,155

 

 

14,155

 

 

14,155

 

2,491

 

(2,491

)

 

 

14,155

 

Income (loss) from continuing operations, including real estate dispositions

 

271,513

 

(3,208

)

268,305

 

(71,511

)

196,794

 

34,461

 

(14,546

)

 

 

216,709

 

Net income (loss) attributable to noncontrolling interest

 

894

 

 

894

 

(112

)

782

 

21,419

 

(21,419

)

 

 

782

 

Income (loss) from continuing operations attributable to common stockholders, including real estate dispositions

 

$

270,619

 

$

(3,208

)

$

267,411

 

$

(71,399

)

$

196,012

 

$

13,042

 

$

6,873

 

 

 

$

215,927

 

Income from continuing operations attributable to common stockholders per common share, including real estate dispositions:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.82

 

N/A

 

$

0.81

 

N/A

 

$

0.59

 

N/A

 

N/A

 

 

 

$

0.65

 

Diluted

 

$

0.82

 

N/A

 

$

0.81

 

N/A

 

$

0.59

 

N/A

 

N/A

 

 

 

$

0.65

 

Weighted average shares used in computing earnings per common share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

327,890

 

N/A

 

327,890

 

N/A

 

327,890

 

N/A

 

N/A

 

 

 

327,890

 

Diluted

 

331,424

 

N/A

 

331,424

 

N/A

 

331,424

 

N/A

 

N/A

 

 

 

331,424

 

 

See accompanying notes to unaudited pro forma condensed consolidated financial statements.

 



 

VENTAS, INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME

For the Year Ended December 31, 2014

(In thousands, except per share amounts)

 

 

 

Ventas
Historical

 

Other 2015 and
2014
Transactions (J)

 

Pro Forma for
Other 2015 and
2014
Transactions

 

CCP Spin-Off
Adjustments (A)

 

Pro Forma for
Other 2015 and
2014 Transactions
and CCP Spin-
Off Adjustments

 

AHS Medical
Holdings LLC
Historical (B)

 

AHS

Transaction

Adjustments (K)

 

 

 

Total Pro
Forma

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rental income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Triple-net leased

 

$

970,377

 

$

44,987

 

$

1,015,364

 

$

(327,490

)

$

687,874

 

$

 

$

105,000

 

(L)

 

$

792,874

 

Medical office buildings

 

463,618

 

110,167

 

573,785

 

 

573,785

 

 

 

 

 

573,785

 

 

 

1,433,995

 

155,154

 

1,589,149

 

(327,490

)

1,261,659

 

 

105,000

 

 

 

1,366,659

 

Resident fees and services

 

1,552,951

 

155,454

 

1,708,405

 

 

1,708,405

 

1,760,021

 

(1,760,021

)

 

 

1,708,405

 

Medical office building and other services revenue

 

29,364

 

 

29,364

 

2,500

 

31,864

 

 

 

 

 

31,864

 

Income from loans and investments

 

55,169

 

880

 

56,049

 

(3,400

)

52,649

 

 

 

 

 

52,649

 

Interest and other income

 

4,267

 

11

 

4,278

 

(2

)

4,276

 

266,847

 

(266,847

)

 

 

4,276

 

Total revenues

 

3,075,746

 

311,499

 

3,387,245

 

(328,392

)

3,058,853

 

2,026,868

 

(1,921,868

)

 

 

3,163,853

 

Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest

 

376,842

 

53,568

 

430,410

 

(24,895

)

405,515

 

87,170

 

(54,964

)

(M)

 

437,721

 

Depreciation and amortization

 

826,911

 

167,115

 

994,026

 

(116,953

)

877,073

 

103,253

 

(67,759

)

(N)

 

912,567

 

Property-level operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Senior living

 

1,036,556

 

105,736

 

1,142,292

 

 

1,142,292

 

1,831,365

 

(1,831,365

)

 

 

1,142,292

 

Medical office buildings

 

158,542

 

20,939

 

179,481

 

 

179,481

 

 

 

 

 

179,481

 

 

 

1,195,098

 

126,675

 

1,321,773

 

 

1,321,773

 

1,831,365

 

(1,831,365

)

 

 

1,321,773

 

Medical office building services costs

 

17,092

 

 

17,092

 

 

17,092

 

 

 

 

 

17,092

 

General, administrative and professional fees

 

121,746

 

11,756

 

133,502

 

(10,000

)

123,502

 

 

 

 

 

123,502

 

Loss on extinguishment of debt, net

 

5,564

 

 

5,564

 

6,881

 

12,445

 

 

 

 

 

12,445

 

Merger-related expenses and deal costs

 

45,051

 

 

45,051

 

(1,547

)

43,504

 

 

32,262

 

(P)

 

75,766

 

Other

 

38,925

 

 

38,925

 

(13,183

)

25,742

 

 

 

 

 

25,742

 

Total expenses

 

2,627,229

 

359,114

 

2,986,343

 

(159,697

)

2,826,646

 

2,021,788

 

(1,921,826

)

 

 

2,926,608

 

Income (loss) before loss from unconsolidated entities, income taxes, discontinued operations, real estate dispositions and noncontrolling interest

 

448,517

 

(47,615

)

400,902

 

(168,695

)

232,207

 

5,080

 

(42

)

 

 

237,245

 

(Loss) income from unconsolidated entities

 

(139

)

 

(139

)

 

(139

)

 

3,000

 

(O)

 

2,861

 

Income tax benefit

 

8,732

 

21,409

 

30,141

 

 

30,141

 

62,517

 

(62,517

)

 

 

30,141

 

Income (loss) from continuing operations

 

457,110

 

(26,206

)

430,904

 

(168,695

)

262,209

 

67,597

 

(59,559

)

 

 

270,247

 

Gain on real estate dispositions

 

17,970

 

 

17,970

 

61

 

18,031

 

148,962

 

(148,962

)

 

 

18,031

 

Income (loss) from continuing operations, including real estate dispositions

 

475,080

 

(26,206

)

448,874

 

(168,634

)

280,240

 

216,559

 

(208,521

)

 

 

288,278

 

Net income (loss) attributable to noncontrolling interest

 

1,419

 

 

1,419

 

(185

)

1,234

 

39,302

 

(39,302

)

 

 

1,234

 

Income (loss) from continuing operations attributable to common stockholders

 

$

473,661

 

$

(26,206

)

$

447,455

 

$

(168,449

)

$

279,006

 

$

177,257

 

$

(169,219

)

 

 

$

287,044

 

Income (loss) from continuing operations attributable to common stockholders per common share, including real estate dispositions:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

1.61

 

N/A

 

$

1.39

 

N/A

 

$

0.86

 

N/A

 

N/A

 

 

 

$

0.89

 

Diluted

 

$

1.59

 

N/A

 

$

1.37

 

N/A

 

$

0.86

 

N/A

 

N/A

 

 

 

$

0.88

 

Weighted average shares used in computing earnings per common share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

294,175

 

28,415

 

322,590

 

N/A

 

322,590

 

N/A

 

N/A

 

 

 

322,590

 

Diluted

 

296,677

 

29,533

 

326,210

 

N/A

 

326,210

 

N/A

 

N/A

 

 

 

326,210

 

 

See accompanying notes to unaudited pro forma condensed consolidated financial statements.

 



 

VENTAS, INC.

NOTES AND MANAGEMENT’S ASSUMPTIONS TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1 - BASIS OF PRO FORMA PRESENTATION

 

Ventas, Inc. (“Ventas” or the “Company”) is a real estate investment trust (“REIT”) with a geographically diverse portfolio of seniors housing and healthcare properties in the United States, Canada and the United Kingdom.  The historical consolidated financial statements of Ventas include the accounts of the Company and its wholly owned subsidiaries and joint venture entities over which it exercises control.

 

On August 4, 2015, Ventas completed its acquisition of Ardent Medical Services, Inc. (“AHS”).  Concurrent with the closing of the transaction, the Company separated AHS’s hospital operations from its owned real estate and sold the hospital operations to a newly formed and capitalized operating company (“Ardent”).  An entity controlled by Equity Group Investments acquired a majority stake in Ardent, while Ventas retained a 9.9 percent interest and AHS management retained a significant ownership stake.

 

Also, on August 17, 2015, Ventas, Inc. (“Ventas” or the “Company”), entered into a Separation and Distribution Agreement with Care Capital Properties, Inc. (“CCP”), pursuant to which the Company agreed to transfer most of its post-acute / skilled nursing facility portfolio to CCP and distribute all of the Company-owned common stock of CCP to the Company’s stockholders in a distribution intended to be tax-free to the Company’s stockholders (the “Distribution”). The Distribution was effective at 11:59 p.m., Eastern Time, on August 17, 2015 (the “Effective Time”) to the Company’s stockholders of record as of the close of business on August 10, 2015. As a result of the Distribution, CCP is now an independent public company and its common stock is listed under the symbol “CCP” on the New York Stock Exchange.

 

NOTE 2 - ADJUSTMENTS TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

(A)  Reflects the financial statement effects of the spin-off of CCP on August 17, 2015.  Adjustments also reflect the financial statement effects of the transition services arrangement entered into with CCP, a $1.3 billion distribution received by Ventas from CCP and the repayment of $1.1 billion of Ventas indebtedness and related fees.

 

(B) Reflects unaudited historical financial condition and results of operations of AHS Medical Holdings LLC, the 100% parent company of AHS (“AHS Medical Holdings”), as of and for the six months ended June 30, 2015 and the audited historical results of operations of AHS Medical Holdings for the year ended December 31, 2014.  Certain amounts have been reclassified to conform to Ventas’s presentation, including the classification of patient service revenue as resident fees and services, the classification of all operating expenses as senior living property-level operating expenses, the classification of accrued preferred dividends as net income (loss) from noncontrolling interest and the classification of certain noncontrolling interests and redeemable preferred units and accrued dividends as redeemable OP unitholder and noncontrolling interests.

 

(C)  Reflects adjustments to record the acquisition date fair value of the real estate acquired from AHS.  Also, adjustments reflect the elimination of all operating assets and liabilities now owned by Ardent, including senior notes payable and other debt and noncontrolling interest.

 



 

(D)  Reflects the increase over AHS Medical Holdings’s historical investment in real estate based upon Ventas’s initial estimate of the acquisition date fair value for the acquired tangible and intangible real estate assets.  These initial values are as follows (in millions):

 

Land and improvements

 

$

97

 

Buildings and improvements

 

1,137

 

Acquired lease intangibles

 

77

 

Initial fair value of net real estate investments

 

$

1,311

 

 

(E)        Reflects the issuance in July 2015 of $500.0 million aggregate principal amount of 4.125% senior notes due 2026 and proceeds from an August 2015 $900.0 million five year variable rate term loan, partially offset by $1.4 billion of cash paid at closing of the AHS transaction.

 

(F)         Reflects the payment of deferred financing costs related to the July 2015 senior note issuance and the August 2015 term loan proceeds.

 

(G)       Reflects the value of Ventas’s 9.9% ownership interest in Ardent.

 

(H)      Reflects the issuance in July 2015 of $500.0 million aggregate principal amount of 4.125% senior notes due 2026 and proceeds from an August 2015 $900.0 million five year term loan, partially offset by the elimination of $870.5 million of AHS Medical Holdings LLC debt not assumed as part of the transaction.

 

(I)  Reflects certain opening balance sheet liabilities of $7.9 million related to the real estate assets acquired as part of the AHS transaction.

 

(J)           Adjustments reflect the financial statement effects of Ventas’s January 2015 acquisitions of American Realty Capital Healthcare Trust, Inc. (“HCT”) and 12 skilled nursing facilities, of which certain HCT properties and all 12 skilled nursing facilities were included in the spin-off of CCP on August 17, 2015.  Adjustments also reflect the Company’s senior note debt issuances and maturities during the six months ended June 30, 2015 and the year ended December 31, 2014, as if those transactions were consummated on January 1, 2014.

 

The adjustment to general, administrative and professional fees reflects the actual savings that Ventas expects to realize after the spin-off, which is lower than its allocation of historical expenses to CCP, due to costs related to corporate functions that both CCP and Ventas will incur as independent publicly traded companies, such as executive oversight, treasury, finance, legal, human resources, tax planning, internal audit, financial reporting, information technology and investor relations.

 

(K)       Reflects adjustments to record the income statement effect of the AHS transaction. Also, adjustments reflect the elimination of all income and expense items related to AHS Medical Holdings LLC, the 100% parent company of AHS.

 

(L)        Adjustment reflects $105.0 million annual rental income to be received relating to the leases of the AHS real estate.

 

(M)    Adjustments reflect the financial statement effects of Ventas’s issuance in July 2015 of $500.0 million aggregate principal amount of 4.125% senior notes due 2026 and an August 2015 $900.0 million five year variable rate term loan.

 



 

AHS Acquisition Adjustments

 

(N)       Based on its initial estimate of the acquisition date fair values of real estate from the AHS transaction, Ventas expects to record the following fair values to the asset classes: $97 million to land and improvements, $1.1 billion to buildings and improvements, and $77 million to acquired in-place lease intangibles. Depreciation expense is calculated on a straight-line basis based on Ventas’s fair value determinations and its estimates of the remaining useful lives of each asset.  The adjustment to depreciation and amortization reflects the following components (in thousands):

 

 

 

Weighted
Average
Useful Life
(Years)

 

For the Six Months
Ended June 30,
2015

 

For the Year Ended
December 31, 2014

 

Ventas’s AHS acquisition adjustments for depreciation and amortization, by asset type:

 

 

 

 

 

 

 

Land improvements

 

9

 

$

961

 

$

1,922

 

Building and improvements

 

40

 

15,473

 

30,947

 

In-place lease intangibles

 

30

 

1,313

 

2,625

 

Adjustment for depreciation and amortization

 

 

 

$

17,747

 

$

35,494

 

 

(O)       Adjustment reflects the estimate of Ventas’s proportionate share of net income from its 9.9% ownership interest in Ardent.

 

(P)         Reflects the payment of certain merger related expenses and deal costs at the time of the closing of the AHS transaction.

 



 

NOTE 3 - FUNDS FROM OPERATIONS AND NORMALIZED FUNDS FROM OPERATIONS

 

VENTAS, INC.

UNAUDITED PRO FORMA FFO AND NORMALIZED FFO

For the Six Months Ended June 30, 2015

(In thousands, except per share amounts)

 

 

 

Ventas
Historical

 

Other 2015
Transactions

 

Pro Forma
for Other
2015
Transactions

 

CCP Spin-
Off
Adjustments

 

Pro Forma
for Other
2015
Transactions
and CCP
Spin-Off
Adjustments

 

AHS Medical
Holdings
Historical

 

AHS
Acquisition
Adjustments

 

Total Pro
Forma

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations attributable to common stockholders, including real estate dispositions

 

$

270,619

 

$

(3,208

)

$

267,411

 

$

(71,399

)

$

196,012

 

$

13,042

 

$

6,873

 

$

215,927

 

Discontinued operations

 

(356

)

 

(356

)

 

(356

)

(9

)

9

 

(356

)

Net income (loss) attributable to common stockholders

 

270,263

 

(3,208

)

267,055

 

(71,399

)

195,656

 

13,033

 

6,882

 

215,571

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Real estate depreciation and amortization

 

493,043

 

14,430

 

507,473

 

(67,192

)

440,281

 

42,775

 

(25,028

)

458,028

 

Real estate depreciation related to noncontrolling interest

 

(4,016

)

 

(4,016

)

134

 

(3,882

)

 

 

(3,882

)

Real estate depreciation related to unconsolidated entities

 

2,926

 

 

2,926

 

 

2,926

 

 

 

2,926

 

Gain on real estate dispositions

 

(14,155

)

 

(14,155

)

 

(14,155

)

(2,491

)

2,491

 

(14,155

)

Discontinued operations:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain on real estate dispositions

 

(277

)

 

(277

)

 

(277

)

 

 

(277

)

Depreciation on real estate assets

 

24

 

 

24

 

 

24

 

 

 

24

 

FFO

 

747,808

 

11,222

 

759,030

 

(138,457

)

620,573

 

53,317

 

(15,655

)

658,235

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of financial instruments

 

24

 

 

24

 

 

24

 

 

 

24

 

Non-cash income tax benefit

 

(18,239

)

(2,262

)

(20,501

)

 

(20,501

)

 

 

(20,501

)

Gain on extinguishment of debt, net

 

(18

)

 

(18

)

 

(18

)

 

 

(18

)

Merger-related expenses, deal costs and re-audit costs

 

51,137

 

 

51,137

 

(3,755

)

47,382

 

 

 

47,382

 

Amortization of other intangibles

 

1,182

 

 

1,182

 

 

1,182

 

 

 

1,182

 

Normalized FFO

 

$

781,894

 

$

8,960

 

$

790,854

 

$

(142,212

)

$

648,642

 

$

53,317

 

$

(15,655

)

$

686,304

 

 



 

 

 

Ventas
Historical

 

Total Pro
Forma

 

 

 

 

 

 

 

Income from continuing operations attributable to common stockholders, including real estate dispositions

 

$

0.82

 

$

0.65

 

Discontinued operations

 

(0.00

)

(0.00

)

Net income attributable to common stockholders

 

0.82

 

0.65

 

Adjustments:

 

 

 

 

 

Real estate depreciation and amortization

 

1.49

 

1.38

 

Real estate depreciation related to noncontrolling interest

 

(0.01

)

(0.01

)

Real estate depreciation related to unconsolidated entities

 

0.01

 

0.01

 

Gain on real estate dispositions

 

(0.04

)

(0.04

)

Discontinued operations:

 

 

 

 

 

Gain on real estate dispositions

 

(0.00

)

(0.00

)

Depreciation on real estate assets

 

0.00

 

0.00

 

FFO

 

2.26

 

1.99

 

Adjustments:

 

 

 

 

 

Change in fair value of financial instruments

 

0.00

 

0.00

 

Non-cash income tax benefit

 

(0.06

)

(0.06

)

Gain on extinguishment of debt, net

 

(0.00

)

(0.00

)

Merger-related expenses, deal costs and re-audit costs

 

0.15

 

0.14

 

Amortization of other intangibles

 

0.00

 

0.00

 

Normalized FFO

 

$

2.36

 

$

2.07

 

 

 

 

 

 

 

Dilutive shares outstanding used in computing FFO and normalized FFO per common share

 

331,424

 

331,424

 

 


(1) Per share amounts may not add due to rounding.

 



 

VENTAS, INC.

UNAUDITED PRO FORMA FFO AND NORMALIZED FFO

For the Year Ended December 31, 2014

(In thousands, except per share amounts)

 

 

 

Ventas
Historical

 

Other 2015
and 2014
Transactions

 

Pro Forma
for Other
2015 and
2014
Transactions

 

CCP Spin-
Off
Adjustments

 

Pro Forma
for Other
2015 and
2014
Transactions
and CCP
Spin-Off
Adjustments

 

AHS Medical
Holdings
Historical

 

AHS
Acquisition
Adjustments

 

Total Pro
Forma

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from continuing operations attributable to common stockholders, including real estate dispositions

 

$

473,661

 

$

(26,206

)

$

447,455

 

$

(168,449

)

$

279,006

 

$

177,257

 

$

(169,219

)

$

287,044

 

Discontinued operations

 

2,106

 

 

2,106

 

 

2,106

 

(293

)

293

 

2,106

 

Net income (loss) attributable to common stockholders

 

475,767

 

(26,206

)

449,561

 

(168,449

)

281,112

 

176,964

 

(168,926

)

289,150

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Real estate depreciation and amortization

 

820,344

 

167,115

 

987,459

 

(116,953

)

870,506

 

103,253

 

(67,759

)

906,000

 

Real estate depreciation related to noncontrolling interest

 

(10,314

)

 

(10,314

)

427

 

(9,887

)

 

 

(9,887

)

Real estate depreciation related to unconsolidated entities

 

5,792

 

 

5,792

 

 

5,792

 

 

 

5,792

 

Gain on real estate dispositions

 

(17,970

)

 

(17,970

)

(61

)

(18,031

)

(148,962

)

148,962

 

(18,031

)

Discontinued operations:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain on real estate dispositions

 

(1,494

)

 

(1,494

)

 

(1,494

)

 

 

(1,494

)

Depreciation on real estate assets

 

1,555

 

 

1,555

 

 

1,555

 

 

 

1,555

 

FFO

 

1,273,680

 

140,909

 

1,414,589

 

(285,036

)

1,129,553

 

131,255

 

(87,723

)

1,173,085

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of financial instruments

 

5,121

 

 

5,121

 

 

5,121

 

 

 

5,121

 

Non-cash income tax benefit

 

(9,431

)

(21,409

)

(30,840

)

 

(30,840

)

 

 

(30,840

)

Loss on extinguishment of debt, net

 

5,013

 

 

5,013

 

 

5,013

 

 

 

5,013

 

Merger-related expenses, deal costs and re-audit fees

 

54,389

 

 

54,389

 

(1,547

)

52,842

 

 

32,262

 

85,104

 

Amortization of other intangibles

 

1,246

 

 

1,246

 

 

1,246

 

 

 

1,246

 

Normalized FFO

 

$

1,330,018

 

$

119,500

 

$

1,449,518

 

$

(286,583

)

$

1,162,935

 

$

131,255

 

$

(55,461

)

$

1,238,729

 

 



 

 

 

Ventas
Historical

 

Total Pro
Forma

 

 

 

 

 

 

 

Income from continuing operations attributable to common stockholders, including real estate dispositions

 

$

1.59

 

$

0.88

 

Discontinued operations

 

0.01

 

0.01

 

Net income attributable to common stockholders

 

1.60

 

0.89

 

Adjustments:

 

 

 

 

 

Real estate depreciation and amortization

 

2.77

 

2.78

 

Real estate depreciation related to noncontrolling interest

 

(0.03

)

(0.03

)

Real estate depreciation related to unconsolidated entities

 

0.02

 

0.02

 

Gain on real estate dispositions

 

(0.06

)

(0.06

)

Discontinued operations:

 

 

 

 

 

Gain on real estate dispositions

 

(0.01

)

(0.00

)

Depreciation on real estate assets

 

0.01

 

0.00

 

FFO

 

4.29

 

3.60

 

Adjustments:

 

 

 

 

 

Change in fair value of financial instruments

 

0.02

 

0.02

 

Non-cash income tax benefit

 

(0.03

)

(0.09

)

Loss on extinguishment of debt, net

 

0.02

 

0.02

 

Merger-related expenses, deal costs and re-audit costs

 

0.18

 

0.26

 

Amortization of other intangibles

 

0.00

 

0.00

 

Normalized FFO

 

$

4.48

 

$

3.80

 

 

 

 

 

 

 

Dilutive shares outstanding used in computing FFO and normalized FFO per common share

 

296,677

 

326,210

 

 


(1) Per share amounts may not add due to rounding.

 



 

Unaudited pro forma Funds From Operations (“FFO”) and normalized FFO are presented herein for informational purposes only and are based on available information and assumptions that the Company’s management believes to be reasonable; however, they are not necessarily indicative of what Ventas’s FFO or normalized FFO actually would have been assuming the transactions had occurred as of the dates indicated.

 

Historical cost accounting for real estate assets implicitly assumes that the value of real estate assets diminishes predictably over time.  However, since real estate values historically have risen or fallen with market conditions, many industry investors deem presentations of operating results for real estate companies that use historical cost accounting to be insufficient by themselves.  To overcome this problem, Ventas considers FFO and normalized FFO to be appropriate measures of operating performance of an equity REIT.  In particular, Ventas believes that normalized FFO is useful because it allows investors, analysts and Ventas management to compare Ventas’s operating performance to the operating performance of other real estate companies and between periods on a consistent basis without having to account for differences caused by unanticipated items and other events such as transactions and litigation.  In some cases, Ventas provides information about identified non-cash components of FFO and normalized FFO because it allows investors, analysts and Ventas management to assess the impact of those items on Ventas’s financial results.

 

Ventas uses the National Association of Real Estate Investment Trusts (“NAREIT”) definition of FFO.  NAREIT defines FFO as net income (computed in accordance with GAAP), excluding gains (or losses) from sales of real estate property, including gain on re-measurement of equity method investments, and impairment write-downs of depreciable real estate, plus real estate depreciation and amortization, and after adjustments for unconsolidated partnerships and joint ventures.  Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect FFO on the same basis.  Ventas defines normalized FFO as FFO excluding the following income and expense items (which may be recurring in nature): (a) merger-related costs and expenses, including amortization of intangibles, transition and integration expenses, and deal costs and expenses, including expenses and recoveries relating to the Company’s acquisition lawsuits; (b) the impact of any expenses related to asset impairment and valuation allowances, the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of the Company’s debt; (c) the non-cash effect of income tax benefits or expenses and derivative transactions that have non-cash mark-to-market impacts on the Company’s consolidated statements of income; (d) the impact of future acquisitions or divestitures (including pursuant to tenant options to purchase) and capital transactions; (e) the financial impact of contingent consideration, severance-related costs, charitable donations made to the Ventas Charitable Foundation, gains and losses for non-operational foreign currency hedge agreements and changes in the fair value of financial instruments; and (f) expenses related to the re-audit and re-review of the Company’s historical financial statements and related matters.

 

FFO and normalized FFO presented herein may not be identical to FFO and normalized FFO presented by other real estate companies due to the fact that not all real estate companies use the same definitions.  FFO and normalized FFO should not be considered as alternatives to net income (determined in accordance with GAAP) as indicators of Ventas’s financial performance or as alternatives to cash flow from operating activities (determined in accordance with GAAP) as measures of Ventas’s liquidity, nor is FFO and normalized FFO necessarily indicative of sufficient cash flow to fund all of Ventas’s needs.  Ventas believes that in order to facilitate a clear understanding of Ventas’s consolidated historical operating results, FFO and normalized FFO should be examined in conjunction with net income as presented in the unaudited pro forma condensed consolidated financial statements.

 


Ventas (NYSE:VTR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Ventas Charts.
Ventas (NYSE:VTR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Ventas Charts.